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5Foreword
This report reviews several interesting research results how to govern healthcare in-
formation. Especially it raises a question how to manage information derived from 
biobank research and genetic databases into globally sustainable and socially robust 
healthcare products and services. 
One focus of this study was to compare governance and engagement regimes 
in Canada, Finland, Iceland, Spain, UK and the US, as well as supranational actors, to 
manage the collections, storage, use and commercialization of healthcare and genetic 
data. It also explores the implications that new patient engagement strategies have 
for the creation and deployment of intangible assets and value creation within the 
Finnish innovation system. Moreover, the study identifies what are critical elements 
between the patients, business and the state. Especially what is the sustainability of 
value creation regimes that can be deployed by companies. 
This report was carried out by Aaro Tupasela, Karolina Snell and Jose A. Cañada 
in the University of Helsinki. Tekes wishes to thank the researchers for their thorough 
and systematic approach of biobanks. Tekes expresses its gratitude to steering group 
and all others that have contributed to the study.
Tekes – the Finnish Funding Agency for Innovation
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7Introduction
This study examines governance challenges posed by 
the utilization and translation of biological samples and 
healthcare information derived from biobank research and 
genetic databases into globally sustainable and socially ro-
bust healthcare products and services. The collection, use 
and distribution of human tissue samples, often referred to 
as biobanking or tissue banking, and which include blood 
and diagnostic tissue samples, from which DNA can be 
extracted and analyzed, has become a major political pre-
occupation, not only in national contexts, but also at the 
transnational level (Gottweis 1998) in that increasingly such 
sample collections are expected to produce commercial 
value (Tupasela 2006a). 
Sociologically, studies of the biomedical collection and 
use of human tissue sample collections has developed into 
its own distinct rubric under both the sociology of science 
and technology studies (STS) and medical sociology as well, 
which have sought to examine the different ways in which 
bodies are being commodified and sourced (Schepher-
Hughes and Wacquant 2002). These approaches have pro-
vided important extensions to studies of gifts as a central 
component of exchange (Mauss 2004), materialist analysis 
of production and capital accumulation (see Sunder Rajan 
2006; Marx 1977), as well as providing new insights into 
the motivations and concerns of donors in participating in 
research (see Table 1). In addition, the rapid development 
and expansion of biobanking activities has also given rise 
to a growing literature on the sustainability of these activi-
ties (Albert et al. 2014; Parry-Jones 2014; Watson et al. 2014; 
Vaught et al. 2010).
In Finland, studies have shown that the most impor-
tant reasons that people would allow for their samples to 
be used in research was furthering medical research and 
benefits to future generations. The promotion of com-
mercial ventures was not an important reason for allow-
ing samples to be used (Tupasela et al. 2010; Tupasela et 
al. 2007; Sihvo et al. 2007) and in fact commercialization 
raised doubts among Finns (Snell et al. 2012; Tupasela and 
Snell 2012). Therefore, when considering the sustainability 
of Finnish biobanking it is imperative to consider public 
perceptions and think through the life cycle of tissue sam-
ples and their related health information in a more robust 
and long-term scenario. In a number of other countries, 
issues surrounding the relationship between biobanks 
and the research population have maintained a central 
role in policy-making and politics as well (Epstein 2007). 
In the US, for example, The Centers for Disease Control 
and Prevention (CDC) has placed a great deal of emphasis 
in developing strategies for community engagement in 
an attempt to improve public health, as well as improve 
the quality and applicability of population research (Hal-
deman et al. 2014). Different countries and institutions 
take different approaches to their engagement strategies 
with regard to the general public, as well as the research 
population from which they collect samples (Cañada et 
al. forthcoming).
Table 2. Reasons of Finns to give sample for research purposes.
Would you be willing to give a blood sample for research purposes? n = 1184 (Sihvo et al. 2007)
Yes No I don’t know
84 % 6 % 11 %
Reasons to give sample for research n=1177 (Sihvo et al. 2007)
Furthering medicine 91
Benefits to future generations 82
Finding out own risks 52
Increasing competitiveness of Finnish researchers 30
Duty 9
Promoting business 3
Table 1. Willingnes of Finns to give a blood smaple for research.
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search is not in itself new (Strong 2000), some have argued 
that recent biomedical research practices using tissue 
sample collections constitute a new object of study within 
biomedical research (von Versen 2000, 2). Internationally, 
the formation of networks of biobanks and protocols for 
standards indicates a professionalization of the field itself. 
European networks such as BBMRI signify an intensification 
of the process of sharing as well as data sourcing with re-
gard to himan tissues, as well as related health information. 
This change in the context of use and application of collec-
tions warrants a better analysis of the conditions surround-
ing such changes and their consequences. 
The biomedical use of human tissue collections also 
has important connections with the emergence and analy-
sis of the increased commercialization of research as well 
(Häyrinen-Alestalo and Peltola 2006; Etzkowitz et al. 1998; 
Etzkowitz and Webster 1995). Public-private interaction 
is not a new phenomenon, but rather has been a central 
feature of biomedical research for decades (see Kleinman 
2003; Hietala 1992). During the past two decades, there has 
been an interest in intensifying the process of transforming 
scientific discoveries and knowledge into commercial appli-
cations (Webster and Rappert 2000; Tupasela 2000) and this 
interest has also been reflected with regard to biobanks and 
biomedical research. This can be seen, for example, with the 
development of biobanking network infrastructure invest-
ments, such as BBMRI-ERIC. At the same time, however, 
closer linkages have begun to develop between political 
expectations associated with scientific research, and the 
theoretical explanations related to the role that knowledge 
is seen to play in economic development (Häyrinen-Alesta-
lo 2006). In many cases, however, these perspectives might 
not consider the multivalent nature of participation in re-
search or the challenges in the use of tissue samples and 
health information without the sources of that information 
knowing about it. This discrepancy can also be seen to have 
developed in the healthcare sector as well, where hospi-
tals are playing a more prominent role in the collection and 
curation of samples and patient information. The commer-
cialization of discoveries and applications based on tissue 
sample collections play an increasingly important role in 
how tissue collections are appropriated and how scientific 
knowledge production is organized (Tupasela 2006a). 
The increase in research policies to bolster the com-
mercial application and long-term sustainability of publical-
ly funded research has also been significantly increased by 
the commercial expectations and hopes that are attached 
to knowledge production policies. Biomedical research is 
one such area that has garnered and produced hopes and 
expectations at the policy level (TEM 2014; Academy of Fin-
land 2003; OECD 2001). Theoretically, such forward looking 
expectations have come to be studied under the rubric of 
sociology of expectations (see Brown et al. 2006). According 
to Borup et al. (2006, 285-286), “expectations can be seen 
to be fundamentally ‘generative’, they guide activities, pro-
vide structure and legitimation, attract interest and foster 
investment. Expectations give definition to roles, clarify du-
ties, offer some shared shape of what to expect and how 
to prepare for opportunities and risks.” In considering the 
sustainable operation of biobanks in the Finnish context it 
is important to understand the ways in which hopes and ex-
pectations operate in resource deployment since they may 
play an important role in the ways in which engagement 
practices are framed and developed. In this sense genom-
ics has proven a fertile gound for hopes and expectations.
Towards the end of the last millennium, the quest to 
unravel the whole human genome was starting to come to 
an end, the interest in commercializing university research 
was gaining increasing political and policy traction and the 
hopes and aspirations of developing a new and fruitful busi-
ness sector was starting to look like a real possibility (OECD 
2001). Rose (2001, 5) has noted that this can partly be at-
tributed to the fusion of two large technosciences of the 
21st century, namely biotechnology and informatics. The 
attempts to commodify the bioinformation in the Icelan-
dic Health Sector Database, for example, represented only 
one approach in the production of biovalue by setting up 
an information monopoly for deCode Genetics. Since the 
setting up of deCode, the company has had to go through 
numerous waves of re-funding from the private sector in 
order to maintain its operations. In relation to long-term 
sustainability the case of deCode Genetics and Iceland is 
instructive in that it has highlighted the long-term nature 
of basic research and the difficulties it has in translating 
that research to viable commercial products. This can be 
seen as an example of the challenges which lay in relation 
to the capture of capital value from genomics projects. The 
production of capital value from biomedical knowledge 
is dependent on a number of factors, one of which is the 
BBMRI-ERIC headquarters in Graz, Austria.  
Photo credit: Aaro Tupasela
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formation resources, as well as the ways in which biobanks 
and the policies that are set up to implement them engage 
with the local populations. Alongside the strides in devel-
opment that have taken place within biotechnology, there 
has emerged a large body of literature that has sought to 
examine and understand the social, ethical, financial and le-
gal aspects associated with the developments in the natural 
sciences (Lauβ et al. 2011).
The developments and strives that have been made 
in the biosciences have by no means been unproblematic, 
leading policy makers and politicians alike to developing 
ways in which the communication between science and 
society can be strengthened and bolstered. Given the sig-
nificance that commercialization has been given in relation 
to the production of scientific knowledge (Jacob 2003) and 
its role in economic development (European Commission 
2010), it is important to better understand the connections 
between participants and collectors, as well as the vari-
ous forms of solidarity that these connections may entail 
(Prainsack and Buyx 2013). Although some have argued 
that gift giving serves as the basis of tissue acquisition (cf. 
Titmuss 1970), it should be noted that this perspective is 
highly normative and entails several assumptions about 
the way tissues and information on the body and health 
are acquired, circulated and used. Given the great variety of 
ways in which tissues and information are acquired, it is also 
misleading to assert that the gift-reciprocity axis is the main 
nexus around which tissue economies (Waldby and Mitch-
ell 2006) operate. Tissues are acquired and made produc-
tive through numerous paths which rely often on different 
forms of discourse and arguments for their use and re-use 
(Tupasela 2011). The scope of different types of tissue which 
are collected and stored ranges from blood and cord blood 
for therapeutic treatments to pathology samples and whole 
organs stored for diagnosis and research. The expectations 
of both lay people and professionals working with biobanks 
are based on complex reasoning about the benefits, risks 
and future developments (Tarkkala et al. 2015; Lauβ et al. 
2011).
Within this field, the biomedical collection, storage 
and use of human tissue samples and related health and 
personal information has been an exemplar of the ways in 
which a field of scientific inquiry has made prominent ad-
vances, while at the same time has had to come to grips 
with aligning and dealing with social, ethical and legal con-
cerns. During the past few years a number of international 
companies have been developing new ways in which to col-
lect and analyze genetic information and connect it with 
self-reported health information, namely through genetic 
self-testing. These can be seen as commercial efforts to de-
velop so-called “joint social efforts” in which notions of com-
munity are built in new ways. Companies such as 23andMe 
and deCODEme (deCODEme was shut down in 2013 due 
to the lack of public interest in purchasing genetic test kits) 
have sought to develop business models that utilize the 
very latest technologies in genetic analysis and combine 
them with various forms of social media through which to 
engage customers in their services. Growing commercial 
uses of the data created by the customers has been labelled 
as “the digital patient experience economy” (Lupton 2014). 
Some authors have also noted how biobanking ventures 
Photo credit: Aaro Tupasela
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have sought new ways in which benefits can be distributed 
between a broader range of actors in an effort to foster trust 
and legitimacy (Simm 2005). This has also been extended 
into the realm of policy discourse as to the role that research 
participants have in the governance process (Corrigan and 
Tutton 2004). The innovations that these business models 
represent seek to develop new forms of engagement with 
research subjects and thus develop forms of social inter-
action with customers that are commercially sustainable. 
These kind of participant-centred initiatives use social me-
dia technologies to address concerns, such as privacy and 
trust, but they also try to provide the basis for long-term 
interactive partnerships (Kaye et al. 2012). The main chal-
lenge with this participant-centered approach, however, is 
that it is unsystematic, unlike many of the national research 
projects in Finland, for example.
For public health initiatives, participation in studies is 
a crucial element for success and validity. During the past 
decades, the levels of recruitment of participants to surveys, 
for example, have declined dramatically (Helakorpi et al. 
2011; Raisamo et al. 2011, 17), posing a serious challenge 
regarding the future possibilities to gather relevant scien-
tific and medical data for large studies. From a sustainability 
perspective this can also be seen as a major challenge to le-
gitimacy. The dramatic decline in participation levels raises 
important policy concerns regarding recruitment and its re-
lation to scientific output and innovations. Given that these 
resources play an important role in research and future in-
novations it is crucial to develop mechanisms that support 
and encourage further participation. On the other hand, a 
major challenge for businesses has been gaining access to 
tissue collections maintained by public hospitals, as well as 
public health care record systems, in a sustainable manner 
that does not threaten the legitimacy of public health care 
institutions, but rather helps to build new forms of social 
engagement between the public and private sectors. The 
role of the state as a mediator in this process is crucial in 
that it must strike a balance between public concerns and 
commercial development. 
Accounting for engagement and participation 
in biobanking
Recently, Kowal (2013) has, paradoxically, noted that no 
research using samples and information is disentangled 
from their source, unless they establish and maintain rela-
tionships with the communities from which samples come 
from. In other words, dis-entanglement requires a form of 
entanglement in order for samples to be used without fu-
ture tensions between the sources of the samples and their 
users. This normative observation may provide important 
insight into the development and maintenance of sustain-
able global biobanking initiatives and their relationship 
with the local/national/global context in which they are 
embedded. Citizen participation and involvement is by no 
means a new topic in relation to techno-political legitimacy. 
Arnstein’s (1969) ladder of citizen participation is a classic 
example of the ways in which involvement has been made 
a political issue in relation to planning and development 
where increased levels of involvement are seen to be desir-
able.
Participatory models of engagement rely to a certain 
extent on an understanding that increased participation 
also increases the flow of information in both directions, 
as opposed to being top-down in nature. From a govern-
ance perspective, such a position may hold important pos-
sibilities for interaction in relation to biobanking. Some 
have argued that increased involvement makes visible the 
‘patient work’ (Corbin and Strauss 1985) and ‘clinical labor’ 
(Cooper and Waldby 2014) that sample donors provide in 
order for collections to become possible and operable, as 
well as allows for increased responsiveness to the interests 
and concerns of those who have participated. At the same 
time, however, biobanks tend to, either explicitly or implic-
itly, engage in a type of population branding, whereby par-
ticular characteristics are assigned to the population from 
which they have collected samples (Tupasela 2015). It is, 
therefore one of the goals of this study to examine the dif-
ferent ways in which various biobanking practices around 
the world have sought to maintain (or disregard) links to the 
population from which they have derived their samples to 
try and ascertain in what ways various engagement prac-
tices facilitate (or do not facilitate) and operate within the 
development of global biobanking practices.
A number of recent studies have examined and ex-
plored the role of community engagement (CE) as a central 
aspect of any biobanking governance scheme (Halderman 
et al. 2014; O’Doherty et al. 2011; Shalowitz et al. 2009). Al-
though much of the literature surrounding forms of com-
munity engagement have stemmed from a concern for the 
lack of consideration for the concerns of minorities and vul-
nerable populations in research settings (Israel et al. 1998), 
the basic theoretical assumptions underlying engagement 
with the research population stem from an understanding 
and belief that engaging with the research population will 
bring with it improved understanding of the context in 
which research takes place, as well as improved results in 
the outcomes of the research and public health (McCloskey 
et al. 2011).
Studies of patient activism have also indicated that pa-
tient organizations are increasingly involved in the organi-
zation of research and sample acquisition surrounding spe-
cific diseases and rare conditions (Novas 2007; Rabeharisoa 
and Callon 2002). These novel knowledge making coalitions 
between patients and research organizations, as well as 
companies highlight the ways in which citizen and patient 
participation is in some cases becoming more prevalent 
11
and inclusive in biomedical research (Novas 2007; Epstein 
2007). Callon and Rabeharisoa (2008) have noted that such 
groups play an increasingly important role in the develop-
ment of technoscience, politics and economic life. Studies 
of emerging “knowledge-making coalitions” in biomedical 
research communities have sought to develop a more de-
tailed and robust theoretical understanding of what some 
have termed medical modernization (Hess 2004, 706; see 
also Brown and Zavestoski 2004). Medical modernization 
has been defined as the epistemic challenge by health so-
cial movements (HSM) and complementary and alternative 
medicine (CAM) professions against paternalistic progres-
sivism (Hess 2004), a situation whener traditional medical 
professional seek to assert their authority over medical is-
sues. Medical modernization is a challenge to traditional 
forms of medical authority by patient organizations who 
seek to leverage their networks and resources into mar-
ketable research resources. Biobanking lies at a crossroad 
where patient participation and support is necessary and 
where the medical authority of experts is also exerted and 
expressed in different ways.
A number of national biobanking initiatives have 
sought to draw on a discourse of participation and involve-
ment of citizens in an attempt to garner broader social le-
gitimacy (Tutton and Corrigan 2004). Research on medical 
modernization has much in common with what Nowotny 
et al. (2001, 54) describe as the emergence of social con-
ditions that allow, and necessitate, that “society is able to 
‘speak back’ to science.” The public shaping of science or 
“citizen science” has taken a central role in current social 
studies of the public’s role in a number of research fields, 
including environmental movements and patient advo-
cacy groups (Prainsack 2014; Kerr et al. 1998; see also Fuller 
2000). Along these lines, Barry (2001, 2) has suggested that 
the technological reflects a “political preoccupation with 
the problems technology poses, with the potential benefits 
it promises, and with the models of social and political order 
it seems to make available.” In this context, it is unsurprising 
that the question of engagement practices in biobanking is 
of political and practical interest, particularly as it relates to 
long-term sustainability.
Appropriate engagement strategies can be seen to 
be important when examining resistance and opposition 
movements related to biobanking. The organization Man-
nvernd was created specifically to oppose the deCode Ge-
netics in Iceland being given monopoly rights to use Ice-
landic information without appropriate public debate and 
discussion (Mannvernd 2003). Similarly in Tonga, an Aus-
tralian biotech firm, Autogen, ran into major opposition as 
a result of failures to account for cultural differences and 
customs in Tonga. Despite having signed a contract with 
Tonga’s health ministry to perform research on the popu-
lation, local opposition and churches in the Pacific united 
to oppose such ventures without extensive prior public 
consultation. The opposition was primarily based on the 
fact that the informed consent procedures did not account 
for the extended family system that plays a major role in 
Tongan society. Other oppositions included giving patent 
monopolies to corporations on God-created life forms (Bur-
ton 2002, 443). In Västerbotten county Sweden, where a lo-
cal hospital granted exclusive rights to a private company 
UmanGenomics to its collections of samples and health in-
formation that have been collected for a past study on heart 
disease ran into major difficulties. Despite having com-
mercial rights that were granted by the Swedish Medical 
Research Council and the law on biobanking, the venture 
ran into opposition by the researchers who had conducted 
the original research. The troubles that UmanGenomics had 
with the project have not reduced, however, the public’s 
willingness to participate, but has hindered the use of the 
information that has been collected since one of the major 
obstacles involves the leader of the research project itself. 
A major problem in the conflict was that UmanGenomics 
did not recognize well enough the right of the researchers 
to the data that they have collected (Hoeyer 2004). Trust in 
experts in the UK also suffered due to incidents, such as the 
Alder Hey and Bristol Royal Infirmary incidents where doc-
tors and researchers collected samples from deceased chil-
dren without their parent’s consent. This raised a number 
of important questions concerning the trust in the medi-
cal community in the UK. This has also been reflected in a 
heightened ethical and legal concern in the setting up of 
UK Biobank (see Corrigan and Tutton 2004). 
The lessons that have emerged from such contentious 
events have indicated that the collection and use of bio-
medical tissue samples and related information should not 
be taken lightly. Instead, there appears to be a movement 
towards a more systematic and professionalized field of ex-
perts who run and operate biobanking activities, who take 
engagement with various stakeholders as an important 
function of their overall operations. 
Levels and styles of engagement
The notion of public engagement covers a very broad range 
of theoretical and practical approaches to engaging with 
the research population, as well as the general population 
at large. Some authors have noted that biobanking has 
moved on to a third phase (Biobanking 3.0) whereby there 
is a shift in the focus towards people/patients, funders, 
and research customers. This type of periodization would 
seem to support the idea that engagement practices are 
becoming increasingly important in biobanking activities. 
In general, engagement refers to processes or techniques 
which allow for involvement and communication. As such, 
this also has significant consequences on the epistemic fea-
tures and political connotations that engagement may en-
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tail at a policy, as well as at a practical level. Due to the brod 
range of mechanisms through which involvement can be 
attained, there has not emerged a single form and style of 
involvement which would have come to dominate the filed 
of public engagement. Conceptually there are a number of 
terms that may have a great deal of similarities, but at the 
same time have different historical and contextual mean-
ings in terms of their approach and practical implications 
in application. Notions such as community engagement 
(Haldeman et al. 2014; McCloskey et al. 2011), community-
based participatory research (CBPR) (Shalowitz et al. 2009; 
Israel et al. 1998), public participation (Hansen 2006; Elam 
and Bertilsson 2003), participant-centric intiatives (Kaye et 
al. 2012) sitizen science (Irwin 1995; Prainsack 2014), and 
the digitally engaged patient (Lupton 2013) are only a few 
examples of terminologies and ideas of engagement with 
the public. Kelty and Panofski (2014), for example, have 
identified seven dimensions of participation that have been 
used in the literature on participation. Similarly, Rowe and 
Frewer (2005) have noted that the key concepts have not 
been well defined in the literature or in the policy domain. 
Despite this they have described three general types of en-
gagement: public communication, public consultation and 
public participation. These different types of engagement 
may hold within them numerous different mechanisms 
through which engagement can be enacted. Some of these 
mechanisms include task forces, workshops, focus groups, 
public panels etc. 
Furthermore, engagement may entail different levels 
and styles of action in relation to how involved the organ-
isers of the engagement mechanisms want the public to 
be (Thiel et al. 2014). There may be considerable trade-off 
involved in seeking to engage the public in an intensive 
manner since such practices may be expensive, time con-
suming and yet attract less attention than originally hoped 
for. Similarly, an engagement strategy that is too “light” 
may in turn not provide enough opportunity for dialogue 
and leave both sides of the engagement process without a 
proper understanding of the interests and concerns of the 
other side. In relatin to biobanking, there has emerged a 
broad range of tactics related to engagement, ranging from 
no engagement to on-going and multifaceted forms of en-
gagement (cf. UK Biobank).
Despite the lack of conceptual clarity and definitions 
of the notion of engagement, what all these forms have in 
common in a type of political preoccupation regarding the 
legitimacy and trustworthiness of certain activities. These 
issues are seen as central elements within the broader po-
litical arena in that the biomedical use of human tissuye 
samples collections are expected to play an increasingly 
significant role in economic development. To procure, store, 
use and distribute such resources without sufficient consid-
eration as to the social, ethical and legal concersn related 
to them may prove problematic in relation to long-term 
sustainability.
Blood bank in Madrid. Photo credit: Aaro tupasela
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Methods and Materials
This report is based on a two-year project, which sought to 
understand the forms and styles of engagement that vari-
ous biobanks undertook in six countries: USA, Canada, UK, 
Spain, Finland and Iceland. We selected these countries with 
regard to differences in size, legislative systems, healthcare 
delivery systems, as well as historical context. We have also 
sought to include different types of biobanks; large pro-
spective cohort biobanks, disease specific biobanks, hospi-
tal-based clnical biobanks, publically run biobanks, as well 
as privately owned and operated biobanks (see Table 2). The 
focus of our research was on engagement strategies of dif-
ferent biobanks in these countries. Our data produced also 
results on the ways in which biobanks come about, as well 
as the multifaceted contexts in which they operate. We con-
ducted 26 semi-structured interviews1 with relevant per-
sonnel from different biobanks, as well as biobank networks 
in six different countries. We also conducted interviews with 
policy makers and regulators to develop a broader picture 
of the nature of biobanking in the various countries. Some 
of the interviews were done in person, while others were 
conducted via telephone or videoconference. In addition to 
the interviews, we collected policy material and other rel-
evant material from webpages and other on-line sources re-
lated to bibanking in each country. These materials includ-
ed legislation in the countries, recent policy discussions, as 
well as public debates, which might have taken place in that 
country or region. We have also participated in conferences 
or symposiums arranged by or focusing on biobanks i.e. UK 
Biobank Ethics and Governance Council workshop. The in-
terviews were coded for various themes, including engage-
ment strategies, funding sources, and ethical debates, and 
their relation to the long-term sustainability of biobanking 
activities in those countries. We then proceeded to com-
pare and contrast activities between biobanks to get a bet-
ter picture of the ways in which biobanks conceptualise 
their engagement strategies. These issues were then com-
pared to other variables, such as national legislation and 
practices related to the collection, storage and distribution 
of samples and data. This report provides insights into the 
findings of our two-year study.
In the following sections, we will describe the national 
contexts related to biobanking in six countries; Iceland, 
Spain, UK, USA, Canada and Finland. We first examine the 
historical contexts in which these various biobanking initia-
tives operate, then we describe the legislative and regula-
tory frameworks that surround them, and finally we explore 
the forms of engagement that the various biobanks and ac-
tors have sought to utilize in their biobanking operations.
1 Interviews were conducted in three different languages: English, Finnish and Spanish. All quotes have been translated by the authors trying to 
stay as close as possible to the original meaning. All identifiers have been removed from the quotes for the sake of preserving the privacy of our 
interviewees.
Table 3. Countries and types of biobanks examined.
Finland THL Biobank
Auria Biobank
HUB
AMCH Biobank
FHRB
Population biobank
Clinical biobank
Disease-based biobank
Clinical biobank
Disease-based biobank
Iceland DeCode Population biobank
UK UK Biobank
Confederation of Cancer Biobanks
Population biobank
Biobank network
Spain Basque Biobank
IDIBAPS Biobank
National Biobank Network (Now ‘Biobank Platform’)
Clinical biobank
Clinical biobank
Biobank Network
Canada CARTaGENE
The Tomorrow Project
Canadian Partnership for Tomorrow Project
Population biobank
Population biobank
Biobank network
USA 23andMe Consumer genetics company
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Background and history of biobanking
The first case that we will examine in this study focuses 
on Iceland, which has a small population and excellent re-
cords of its population history. Iceland emerged onto the 
biobanking scene relatively early and some might say it has 
been a quintessential example of a nation-state leveraging 
its population and healthcare records to the use of com-
mercial biomedical research. Surprisingly, unlike Finland, 
Iceland’s population is somewhat more heterogeneous in 
relation to the number and frequency of alleles. Nonethe-
less, it has been seen as a veritable ‘gold mine’ for the study 
of disease aetiology within a relatively homogenous popu-
lation since it has very accurate records through which it is 
possible to trace ancestry. 
Iceland is best known for its association with the de-
Code controversy (Rose 2001) that arose during the turn of 
the millennium when a private company was given monop-
oly rights to the use of national health records. The entrance 
of deCode onto the Icelandic scene was preceded, however, 
by other nationally funded research that had been going 
on for decades before deCode. One major example of this 
is the Icelandic Heart Association and its Reykjavik study 
which examined the causes of heart diseases within the 
capital region. The study began collecting samples already 
back in the 1950s. It was not until 1996 that it began doing 
genetic studies on its research participants. The Heart Asso-
ciation received some of its early funding from the National 
Institutes of Health (NIH) in the USA. Today, the Heart Asso-
ciation is a major collaborator with deCode and one might 
argue that the work that is done by the patient organization 
has had an impact and willingness of people to participate 
in later studies conducted by deCode.
Iceland
Sample cold storage. Photo credit: Aaro Tupasela
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The case of the Icelandic Health Sector database is 
perhaps the best known and first to attract major attention 
around the world. As Rose (2001, 5) has noted, what was 
being traded by giving deCode a 12 year monopoly over 
the health information of Icelanders was not nature itself, 
but information about nature. The Act on Biobanking that 
was passed in 2000 that gave deCode exclusive rights raised 
a number of sharp criticisms against the Icelandic govern-
ment (Pálsson and Harđardóttir 2002). Not only had the 
government given a monopoly to a private company, but it 
had also failed, in the original version of the law to provide 
Icelanders the opportunity to opt-out of the database that 
was being used. As we already mentioned, the organiza-
tion Mannvernd played an essential role in the controversy 
leading 10% of the population to choose to opt-out of the 
database (Mannvernd 2003). The majority of Icelanders, 
however, have chosen to participate in it, which reflects 
research results on the attitudes and acceptance rates of 
the general population towards biomedical research and 
biobanks (Árnason and Árnason 2004; Thorgeirsdottir 2004). 
DeCode sought, however, to set in place a research system 
in which people could trust and feel that they wanted to 
participate in.
It should be noted that deCode has had to go through 
a number of financial restructuring projects. The latest of 
which was at the beginning of 2013, when Amgen pur-
chased deCode. Despite the restructuring, the ethical and 
legal framework that was put in place back when opera-
tions began still were in place preventing samples and data 
from being moved abroad. This, however, was not a prob-
lem for the acquisition for Amgen and it does not appear to 
have caused alarm among Icelanders.
DeCode was not the only start-up company in Iceland. 
Urdur Veldandi Skurd (UVS) was a privately held cancer 
research company operating in Iceland. Like deCode, it 
sought to make use of the Icelandic population and the 
healthcare system to collect data, recruit research subjects 
and develop novel therapies. In 2006, however, UVS was ac-
quired by deCode. As one researcher in Iceland commented 
on the acquisition:
I think maybe their operation was too small to survive, be-
cause they didn’t have the funds to invest in the infrastructure 
that was needed. And, but I mean the operation has been, 
the project is still ongoing here, and it’s one of our more suc-
cessful fields, the cancer. So actually the key people there 
that were interested in joining us were all offered to come 
here, and some of them are still here, some did not want, so.. 
(Interviewee, 2013)
Despite its financial difficulties, the work that was be-
ing carried out at UVS could, as a result of the acquisition, 
be continued at deCode. It should be noted that the work 
of UVS was also very reliant on cooperation with the lo-
cal patient organisation. Despite its small size, Iceland has 
been able to accommodate one of the most famous genet-
ics companies ever created and has managed to weather 
numerous difficult financial situations to produce a large 
amount of research results based on the Icelandic popula-
tion.
Legislation
Biobanking in Iceland is regulated through the Biobanks 
Act, No 110/20002 and Regulation No 1146/2010, on the 
storage and utilization of biological samples in biobanks. 
The scope of the Act applies to the collection of biological 
samples, as well as their keeping, handling, utilisation and 
storage in biobanks. The Act does not cover the short term 
storage of samples which are collected for clinical testing, 
treatment, or for specific scientific studies. These samples 
must be destroyed when the tests, treatment or research 
are completed. Temporary storage has been defined as 
storage for up to five years, unless the National Bioethics 
Committee authorises a longer period. If the samples need 
to be stored or preserved for a longer period, they should 
be stored in a biobank. 
The Icelandic legislation defines a biobank as a collec-
tion of biological samples which are permanently preserved. 
From a research perspective, however, this is problematic 
since using samples ultimately will lead to their destruction, 
while at the same time converting the biological material 
into data-based format. Biobank samples only have a finite 
number of times that they can be used before the sample 
material is exhausted. Research biobanks are defined as col-
lections of research samples to be preserved for more than 
five years, while clinical biobanks are collections of clini-
cal samples to be preserved for more than five years. The 
scope and purpose of the biobank legislation is to authorise 
the collection, keeping, handling and utilisation of human 
biological samples so that confidentiality is ensured, the 
interests of donors of biological samples are safeguarded 
and that the utilisation of the biological samples serves 
the purposes of science and medicine, and is conducive 
to the public good. The license to operate a biobank is is-
sued by the Minister of Health. The responsible party for the 
biobank shall be responsible for the implementation of in-
ternal monitoring, and that security assessments are carried 
2 A legislative proposal for a new Act on Biomedical Research was put before Althingi in November 2013. Amendments to the Biobanks  
Act will be made simultaneously.
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out regularly. The Data Protection Authority is charged with 
monitoring the security of personal data in biobanks, while 
the National Bioethics Committee oversees the activities of 
research biobanks. The Directorate of Health monitors the 
activities of clinical biobanks (NCBio 2014).
In acquiring samples informed consent is required if 
samples are collected for research purposes. As per inter-
national standards, the consent must be given freely and 
in writing after the donor of a biological sample has been 
given information regarding the objective of the sample 
collection, the benefits, risks associated with its collection, 
and that the biological sample will be permanently stored 
at a research biobank. Presumed consent may be used if 
the sample is stored in clinical biobank and the sample 
was originally collected for diagnostic purposes, provided 
that general information on this is provided by a health-
care professional or health institution. Sample donors are 
allowed to opt out at any time – but in the case of a biobank 
with clinical samples, the board of the biobank may, with 
the approval of the National Bioethics Committee and the 
Data Protection Authority, authorise the use of the sample 
if important interest are at stake. Interestingly, the biobank 
manager (licensee) is not considered to own the biological 
samples, but rather has right to dispose them under certain 
conditions set forth by the law. The biobank manager is also 
responsible for their proper handling so that it meets the 
provisions of this Act, and of government directives based 
on it. The licensee is not authorised to pass the biological 
samples on to another party, nor use them as collateral for 
financial liabilities, and they are not subject to attachment 
for debt (see NCBio, 2014 for an excellent overview of Ice-
landic legislation).
Although there was some controversy when the Act 
on Biobanking came into force, it appears that deCode has 
been seen as a national success story in Iceland. The law 
that was put in place has been seen by many as serving 
its purpose for the most part. One of the main points that 
were written into the law regarded the handling of samples 
and data from Icelanders. One interviewee discussed the 
conditions that are specified in the law concerning samples 
and data:
no samples will be leaving Iceland, the databank has by law 
and by the operating license to reside here. We are not al-
lowed to transfer health information, we are not allowed to 
transfer individual level data, which we think is very good for 
us, because the operation cannot be transferred from Iceland 
to anywhere else. They will not have access to our data, they 
will have, see our results before they’re published, that sort 
of.. We will continue with the same way of working, with the 
same projects. (Interviewee, 2013)
This can be seen as way to increase trust and willing-
ness to participate in biobank research since there is a high 
level of clarity as to how and in what ways samples and 
data are handled in Iceland. Also our research in Finland 
has showen that people are more willing to participate in 
national efforts and are scptical about samples and data 
going abroad. International cooperation does not guaran-
tee that the benefit come back to own nation and national 
health (Tupasela and Snell 2012).
Engagement practices and social aspects 
related to biobanking
In this study we are looking at forms of engagement that re-
late to biobanking activities in a broader sense. This means 
that engagement does not have to denote an active pro-
cess whereby biobankers or administrators seek actively 
to engage in public debate, discussion or consensus meet-
ings over specific biobanking activities. Rather, engage-
ment with populations and individuals can also be seen to 
take place through mundane practices, such as visits to the 
clinic, as well as the ways in which biobanking activities and 
regulations in and of themselves may engender forms of 
trust and reciprocity between actors. In addition, biobank-
ers engage with a host of other actors, such as companies, 
venture capitalists and authorities in order to maintain the 
operations of biobanks and prevent the operation from go-
ing bankrupt (Tupasela and Stephens 2013). In this sense 
we can argue that biobanking itself is a form of govern-
ance through which daily practices in research, as well as in 
clinical treatment give rise to forms of interaction and trust 
building over time (cf. Hoeyer 2013).
One example of this relates to the ways in which 
biobanks as entities and biobanking practices sometimes 
come about. Although population scale biobanking has 
garnered a great deal of attention recently, many of these 
larger activities have grown out of much smaller efforts to 
study specific diseases. In a number of cases, studies have 
looked at specific families or smaller population isolates 
where the work of clinicians and researchers has perhaps 
been more intimate. One researcher noted this progression 
in an interview regarding Iceland when he said:
And in the beginning it was sort of family based, where we 
have many cases in the family. Now we are very much just re-
cruiting everyone that has a specific diagnosis. (Interviewee, 
2013)
As the task of collecting more samples and people has 
increased, so has the form and style of engagement along 
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with it. With larger population sizes, the ability of people 
involved in research and clinical work changes in relation 
to the population that is being studied. In this sense, en-
gagement practices should be seen as very context and 
practice specific. It also means that engagement practices 
are dynamic in that their original purpose may succumb 
to pressure to leverage their use for new, more ambitious 
uses, whereby new forms of engagement become neces-
sary with new sets of actors.
When discussing the type of consent that deCode has 
with many of its research participants, one interviewee 
noted the following:
No, not all with broad consent, but over, I think it’s about 
120 000 totally, 105 000 that we have (chip typed), and a 
great majority in all diseases have a broad consent. So what 
we are more doing now is not recruiting new people but re-
trieving additional information. And when they sign the con-
sent they also allow us to retrieve any relevant clinical data, 
of course the Ethics Committee has to approve the data. 
They allow us to re-contact them, and for quite many years 
it’s stated that that re-contact can be based on a phenotype 
or on a genotype. So for example if we are interested in re-
cruiting people that have or do not have a specific mutation 
for … we can do that. We will not reveal to them whether 
they have the mutation or not, but we will say, we will recruit 
so many people, half of them have the mutation, half does 
not, or 80 percent have the mutation (the other don’t), be-
cause we are not allowed to give any feedback to them. But 
we can still recruit based on a genotype (-). Then they also 
allow us to, that we contact them to ask them to, ask their 
relatives, family members to come, and so on. And they allow 
us both to re-contact them for additional studies and also to 
answer questionnaires or come and get new samples and so 
on. (Interviewee, 2013)
The above interview excerpt highlights the way in 
which engagement has been framed very clearly within the 
informed consent framework and that formal re-contact is 
based on the needs of the researcher. At the same time the 
legal framework also prohibits the researcher from provid-
ing any information regarding possible findings in the re-
search. These clauses in the informed consent framework 
set very clear boundaries for what is expected and allowed 
among those who are involved in the biobanking process. 
It also has clear consequences in relation to what research 
subjects may expect to receive back from the studies, which 
in this case does not include any information on personal 
risks. while the return of results may have been framed in 
a different way when research was conducted at a smaller 
scale, such as in family studies, the scaling up of activities 
has meant that researchers seeking to set up a larger col-
lection have been confronted with a new set of actors and 
problems with which they need to engage with. In many 
western countries, this form of engagement can be seen as 
being highly contractual in nature. This point regarding the 
contractual nature is further highlighted in the following 
interview excerpt:
I: Yeah, so, that will, when you give broad consent it means 
that you will be in some form of engagement with…
R: Yeah, we can contact them, but they can always refuse, 
(--) but they, now it’s really stated that they allow us to re-
contact them, and then we do it by sending them a letter 
saying now we have a new study, do you want to participate, 
and they just say yes or no. And of course they can any time 
leave a study. We have less than ten that have left the whole 
studies, in the 16 we have been operating, so.. (Interviewee, 
2013)
In discussion of what the researchers felt that they were 
able to give back as a result of their work, they discussed the 
significance of their work in relation to the translation of the 
research into practical benefits. One researcher noted that:
we are providing I think seven tests now, for, diagnostic pur-
poses. Risk assessments that are CLIA certified and, so we can 
actually provide this genetic testing in the US through the 
health system there, and are doing so. (Interviewee, 2013)
In some cases the legal framework that has been set up 
to govern the biobanking and research process was felt to 
be problematic in terms of return of individual research re-
sults to participants. In relation to engagement this is an im-
portant feature that many biobanks are dealing with; how 
to deal with incidental findings, as well as individual results 
in biobank research? For some participants in biobanking 
studies have shown that people’s reason for participating 
was related to them being able to receive health informa-
tion on themselves (Sihvo et al 2007, Snell et al. 2012; Meu-
lenkamp et al. 2010). With the case of Iceland this is not al-
lowed within the legal framework which some interviewees 
considered a hindrance and problem in terms of uptake of 
research results from biobank research:
so that is the obstacle when we feel that the health system 
is not ready yet to make use of what they should use, or 
what they could use, however you like to look at it. But of 
course, everything we publish can be translated into the 
diagnosis, and of course like for BRCA, it’s used, all women 
in the US who can afford, they have a BRCA test. (Inter-
viewee, 2013)
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This ‘obstacle’ should not be seen simply as a problem 
to the translation of research, but also as a trust building 
mechanism within the Icelandic society. As one researcher 
noted:
So I think the strict regulations that deCODE was set under 
and then the Heart Association followed, the (UVS) followed, 
were really improving a lot the conditions that we had. And I 
think the Bioethics Committee in general has functioned very 
well. There have been sometimes delays, big projects have 
been started and people want to go through very thoroughly 
and so on, but in principle I think it has worked quite well. 
It has been difficult for those that are working in the public 
sector to meet the requirements. Because I mean they feel 
the paperwork is heavy and so on, and.. (Interviewee, 2013)
So within the context of the legislative framework in 
Iceland the law acts both as a type of hindrance in relation 
to bureaucracy, paperwork and limiting the return of inci-
dental findings and individual research results to people, 
but it can also act as a mechanism that builds trust in the 
system itself by creating a formal system in which trans-
actions and re-contact operate. The forms and object of 
engagement that biobank managers need to participate 
in do not only relate to research participants (with whom 
their engagement is limited through legislation), but rather 
a much larger and broader set of actors, including ethics 
committees, government authorities, as well as venture 
capitalists who may provide the financial backing for the 
operation.
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Background and history of biobanking
The history of biobanks in Spain goes back to the 1980s. In 
1985, the first collection of biological tissues was established 
in Barcelona, inside the Institute of Biological Research Au-
gust Pí I Sunyer (Institut de Investigaciones biològiques 
August Pí i Sunyer, IDIBAPS). This first collection would not 
become a biobank until 2006, after the enactment of the 
new Biomedical Research Law (Ley de Investigación Biomé-
dica, LIB). In Spain, as we will see in the section about the 
legal framework, collections and biobanks have different 
legal status. Until the enactment of the law, biological mate-
rial would be organized in small and individual collections. 
Nevertheless, this does not mean that such collections were 
completely isolated. During the 1990s, Spain was a pioneer 
with the creation of the first biobank cooperative network. 
This biobanking model, has served as an example for many 
other countries when it comes to organizing a shared ef-
fort to face complex research designs, which requires criti-
cal mass. This pioneering cooperative project was named 
the National Network of Tumor Banks.
Then, we did not have easy access to samples. This led us 
to imagine and start some sort of collaboration network 
between different hospitals and we promoted and started 
what we then called the National Network of Tumor Banks in 
which we got to associate up to 20 hospitals in whole Spain 
with which we had a treatment of privilege, in the sense that 
when we needed some sort of sample we would request 
them and they would send them to us. That way we created 
what possibly was, and not only possibly, in my knowledge, 
the first experience of a cooperative network, definitely in Eu-
rope, but possibly in the world” (Interviewee, 2014)
This network would later become the Spanish National 
Network of Biobanks, which was recently renamed as the 
Biobank Platform. It served as a guide for many interna-
tional cooperative network models (Romeo Casabona et al. 
2011). What made the Spanish case special was its open and 
cooperative character.
Another big temporal marker took place in 2007, when 
the Biomedical Research Law (Ley de Investigación Biomé-
dica, LIB) was enacted. This changed the whole system. 
Since then, collections, in order to be recognized, need to 
be registered as biobanks. Therefore, collections are turned 
into biobanks all around Spain at the same time as new 
biobanks are founded. But in order to keep the collabora-
tive frame going, the Instituto Carlos III began the National 
Network of Biobanks (Red Nacional de Biobancos, RNBB). 
This network has been helping with the initial stages of set-
ting up many biobanks (as most of them were just react-
ing to the Biomedical Research Law). Since biobanking has 
become a bit more stabilized, and despite the economic 
problems, the RNBB has begun a new phase, marked by the 
name change to the Biobank Platform, where they will fo-
cus more on research and collaborative endeavors.
Spain
Field collection bag for samples. Photo credit: Aaro Tupasela
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One of the first organizations to turn collections into 
biobanks was the Basque Biobank. This biobank is a net-
work biobank that organizes and coordinates 9 different 
hospitals in the Basque Country turning them into a single 
entity considered a biobank. This kind of model is catego-
rized in the LIB as a “network biobank”. Because of its early 
creation (founded in 2003), this experience meant a very 
innovative approach in the Spanish context and was able to 
have a prominent role in the development of the LIB.
Currently, the Spanish national registry of biobanks, 
administered by the Instituto de Salud Carlos III contains 
listings for 90 biobanking entities3. Only collections regis-
tered in the biobank registry as such have the qualification 
of biobank. A study carried out by the National DNA Bank 
in 2005 (Romeo Casabona et al. 2011, 312), showed some 
interesting data. Geographical distribution of biobanks is 
quite irregular as 70% of the facilities are located in Madrid 
and Barcelona, the two biggest cities in the country. The 
oldest biobanks were hosted and created by hospitals and 
more than 90% of the total amount had been created from 
2001 onwards. No new studies have been carried out since 
the implementation of the LIB.
One of the latest defining events for the Spanish 
biobanking industry was the rejection by the Spanish gov-
ernment to take part in the European biobanking network 
BBMRI because of disagreements in the representation sys-
tem. Because of this, all the responsibility to take part in in-
ternational activities is left to individual biobanks instead of 
being channeled through the RNBB. This makes the interna-
tional projection of the Spanish biobanking sector difficult. 
Nevertheless, we can find some examples where a Spanish 
biobank is leading international research projects, such as 
the Biopool project, led by the Basque Biobank. 
Another defining feature of the biobanking landscape 
in Spain is the financial crisis, which has been a big setback 
for the development of the sector. The amount of available 
funding coming from public institutions has decreased sig-
nificantly to the point that many biobanks needed to be 
left out of the RNBB in terms of funding although the plan 
is for them to be incorporated later to the governing or-
ganism without receiving any extra funding for it (as the 
current 52 members do receive). A final important point to 
take into account is the fact that the first Spanish Bioethics 
Committee was not set up until 2008, as a consequence of 
the enactment of the LIB.
Legislation
In Spain, biobanking is regulated mainly by the Biomedical 
Research Law, which was enacted in 2007 (Ley 14/2007, de 
3 de julio, de Investigación biomedical, LIB4). This was com-
plemented by the Royal Decree 1716/2011[3], which es-
tablishes the basic requisits to authorize and run a biobank 
with the objective of biomedical research and the treat-
ment of biological samples of human origin. The Royal De-
cree also regulates the functioning of the National Registry 
of Biobanks. As we discussed in the previous section, there 
are two different pathways for the collection of biological 
samples in Spain:
 • Biobanks: a private or public establishment, non-profit 
organisation, which host a collection of biological sam-
ples conceived with the objective of diagnosing or 
doing biomedical research and organized as a technical 
unit with quality standards, order and end use. It also 
needs to be registered in the National Biobanks Registry.
 • Sample collections: anything that does not fit the defini-
tion of biobank needs to be considered a collection of 
biological samples.
In the field of biobanking, a biological sample is defined as 
“any biological material of human origin that is susceptible 
to conservation and that may contain information about a 
person’s genetic characteristics” (Art. 3, LIB). This excludes:
 • Whole organs not susceptible to preservation while 
maintaining their structure, vascularization, and capac-
ity to develop physiological functions with a significant 
degree of autonomy.
 • Gametes (as they do not include an individual’s com-
plete genetic information)
 • Human embryos and fetuses (nevertheless, cells and tis-
sues extracted from them are considered samples)
For a biobank to receive authorization, at least three re-
sponsibility positions need to be fulfilled in the organiza-
tional chart of the biobank: a director/owner, a scientific 
director, and a file supervisor. The biobank is also required 
to be in constant contact with two different external bioeth-
ics committees: a scientific and an ethical one.
3 A public list can be found at https://biobancos.isciii.es/ListadoBiobancos.aspx
4 The State Official Bulleting (BOE) which describes the enactment of the law can be found at  
https://www.boe.es/boe/dias/2007/07/04/pdfs/A28826-28848.pdf
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Biobanks, depending on the internal organization and 
their projection, can be categorized in four different cat-
egories:
1. Hospital biobanks: biobanks associated to a hospital. 
This means that most of the collection and research ac-
tivities are carried out inside the same institution.
2. Biobank networks: cooperative systems between differ-
ent biobanks.
3. Network biobanks: biobanks that count as a single en-
tity, but that have their samples and collection centers 
scattered among different geographical points (usually, 
different hospitals).
4. National banks: biobanks that have a national scope.
One of the controversial points in the biomedical law is 
related to informed consent. This point has been treated 
very carefully in the LIB in terms of what kind of information 
needs to be included in the document. So, any informed 
consent document needs to include, at least, the following 
information (Romeo Casabona et al. 2011):
1. Purpose of the research
2. Expected benefits (both for donor and society)
3. Potential inconveniences associated to the collection 
procedure
4. Identity of the person responsible for the research
5. Right to revoke the consent
6. Place where the analysis will be performed
7. Right to know the genetic information obtained from 
the analysis
8. Ensuring the confidentiality of the information by indi-
cating the identity of individuals with access to the sam-
ple
9. Possibility of knowing information regarding their 
health from the genetic analysis and the right to choose 
whether or not to be given this information
If the sample is to be anonymized, only conditions 1, 2, 3 
and 4 are necessary. Consent can be revoked at any time. 
In addition to the above 9 points, it is also appropriate to 
provide the following information:
1. the sample should be given freely
2. the subject does not have any economic rights on the 
sample
3. the source of financing for the research
4. Individual and family have the right to use the sample 
for health purposes
5. If the sample is preserved: conditions of its preservation, 
objectives, future uses, transfer to third parties and con-
ditions for sample withdrawal.
Regarding the collection process, if the risk of an in-
vasive procedure is considered to be high, the collection, 
and the consquente research, cannot take place at all. In 
case of the risk evaluation allowing the collection, invasive 
procedures must always be insured. 
As for the ownership of the sample, this point is not 
clear within the law. What seems to be clear is that the do-
nor waives all financial rights or other kind of rights derived 
from the results (Art. 7). Other than that, the law does not 
cover what happens to the sample in terms of ownership 
when it moves from one custodian to another.
In terms of anonymization, we can find three types of 
samples: a) biological samples associated with an identified 
person, b) biological samples associated with an identifi-
able person and, c) anonymous biological samples. When 
talking about privacy, there are some data which are more 
sensitive than other. High level measures of confidentiality 
to be applied with regard to ideology, union membership, 
religion, beliefs, racial origin, health, or sexual lifestyle (Art. 
81.3).
Regarding feedback to the donor, there are three 
points to take into account: 1) the donor has the right to 
access general results of the research, 2) If the donor re-
quests so, she will be informed about relevant health issues 
derived from the analysis of her samples, and 3) even when 
not especially relevant, the donor can still access the infor-
mation.
The enactment of the LIB has provoked some conse-
quences that have changed the landscape of biobanking 
in Spain. Mostly, it has forced many institutions to take a 
more stable and better defined legal form. In addition, the 
law has influenced the liberty of biobanks to interact with 
patients.
Engagement practices and social aspects 
related to biobanking
In the interviews with Spanish biobankers, it was interesting 
to see how the idea of engagement was developed. While 
most literature pays attention to the engagement with the 
public, and we did stress this point in our interviews, the 
conversation always turned towards other actors that also 
need to be engaged with, but are usually not considered 
in those terms. The list includes other biobanks, industry, 
doctors, clinicians, researchers, funding organizations, pub-
lic administration and, of course, patients and donors.
Biobanks are rarely able to exist on their own. It is 
much more common to find them associated with other 
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biobanks and being part of a network. Such coexistance is 
more or less difficult, but it is, in any case, decisive for their 
survival. Engaging with one another and cooperating al-
lows them to participate in larger research projects, which 
is sometimes difficult for an individual biobank. This kind of 
framework offers a very specific kind of sinergy that makes 
“one plus one be more than two” (Interviewee, 2014). Hav-
ing biobanks working together allows for more complex 
strategies to achieve quality. This includes harmonization 
of data collection for all the members of the network. But 
once this is done, the capacity of the network to cover the 
necessities of researchers is increased greatly. But this is not 
only the pooling of samples, it is also a combination of ef-
forts. They may set common goals and common strategies 
to pursue them.
Another necessary relation for biobanks is the one 
they hold with different sources of funding. This seems 
to be an especially relevant topic in Spain as the financial 
crisis has impacted greatly on the whole research sector, 
making biobanks very difficult to become sustainable eco-
nomically. Charities, in comparison to other countries such 
as in the UK, do not play a role at all. Most funding comes 
from the public administration, but this seems to not be 
sufficient. Furthermore, sometimes the public administra-
tion does not have the time or the resources to even pay 
attention to biobanks that they have themselves helped to 
set up. The relationship is sometimes reduced to authori-
zation and funding of the biobank. Therefore, many hopes 
are put in the private industry, although there seems to be 
many difficulties to engage with this sector. In other cases, 
as the one of the Basque Biobank, there is a successful re-
lationship with the public administration. In this case, the 
public department of industry provides more support to 
the Basque Biobank than the health department. This al-
ready marks the orientation of the creation of the biobank, 
which is focused more at developing biotech industries that 
can render products than at interacting directly with health 
institutions.
Because of this funding issue and, as it happens in most 
of the other analyzed countries, the private/public dichoto-
my is always central to the discussion. Collaboration is not 
only necessary among biobanks but also with industry. To 
carry out activities, funding is necessary and the national or-
ganisations are not able to reach the required level of fund-
ing to utilize the potential of the collected samples. Lack 
of funding or disinterest from part of industry may lead to 
underuse of samples.
Despite the difficulty of engagement with industry, 
when it does takes place, the objectives are more shared 
than one would think:
Then, the difference, as you will well know, is that, one thing 
is a SME, a for-profit enterprise to distribute among associ-
ates and stockholders, but we are also for profit with that 
know how that we are investing, so to get more funding to 
be able to reinvest it. [...]. Logically, the interests are different 
but the strategy and the objectives are very similar. (Inter-
viewee, 2014)
As can be seen in the last fragment, biobanks also look 
for profit although their objectives are quite different from 
those of private companies. While companies are interested 
in creating profit to be shared among stakeholders, public 
biobanks look to create profit that can be reinvested in their 
own activity in order to keep developing as a biobank. This 
appears again as a way of solving the funding problem. If a 
biobank is able to produce money, it will be able to survive 
on its own. If not, it will always depend on public funding 
(not always available) or private funding (difficult to secure 
in a stable manner).
One interesting example of engagement with the pri-
vate sector is the agreement between the Basque Biobank 
and some funeral homes. The Basque Biobank pays funeral 
homes in order to arrange the transportation of samples for 
the brain biobank. This shows how biobanks need to be cre-
ative in order to maximize efforts and resources in order to 
achieve high quality connections. This sort of engagement 
maximizes costs and it translates into an improvement of 
the samples to increase knowledge.
According to one of our interviewees, biobanks should 
aspire to be the most useful and rentable resource for the 
biomedical industry. The orientation of the biobanking sec-
tor in Spain seems to clearly lean towards the interaction 
with the private sector and that seems to be the future for 
the sector if it wants to achieve sustainability.
Another common way of looking for funding is through 
international engagement. Sustainability and globality are 
deeply intertwined in many cases and it seems difficult to 
achieve the former without the latter. The situation in Spain 
is now especially complicated as the central government 
refused to fund the entrance of the RNBB into the BBMRI. 
Therefore, the responsibility of international engagement 
has been left to individual biobanks. This way, Spain has 
lost its representation in the most important European 
biobanking association and international engagement has 
been seriously hindered.
Engagement with the public administration is not 
only relevant because of the funding possibilities. Another 
way of interacting with public administration is related to 
the the creation of the biobank law. Being able to engage 
with lawmakers, thanks to the expertise of biobankers, 
has made it much easier for biobanks to later adapt to the 
law. By helping to develop it, the law will be shaped more 
similarly to the way biobanks actually operate. If, on the 
other hand, the biobank needs to react to it, this means the 
biobank needs to adapt to it and carry out more changes. 
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This has been the case if we compare the Basque Biobank 
and IDIBAPS. Established in 2003, the Basque Biobank was 
able to lead and indicate the path for the development 
of the law, having therefore less problems to adapt to it. 
IDIBAPS, on the other hand, has been struggling to adapt to 
the new law when it was enacted. Being able to participate 
in the development of the law has probably made iteasier 
for the Basque Biobank to adapt to it as many points were 
developed inspired by the way the Basque Biobank was al-
ready working.
Sometimes, when paying attention to these more bu-
reaucratic issues, it seems easy to lose focus on what are the 
primary objectives of a biobank. So that funding and those 
high quality collections can be properly used, biobanks also 
need to engage researchers in their plans. This proved to be 
difficult in the case of the RNBB as researchers are not used 
to the biobank format. They were not willing to share their 
samples and did not understand that that did not mean 
they were going to be taken by other researchers. Because 
of that, the RNBB had to spend several years teaching re-
searchers what biobanks actually are. This opinion is shared 
also by the Basque Biobank, where they think they need to 
educate the researchers, as well as the clinicians.
One of the consequences of engaging clinicians is that 
they are in constant contact with patients. This is what we 
call mediated engagement, engaging one community al-
lows to engage another one. This is important because en-
gagement of the public is a very complicated process. It is 
highlighted as an important issue but the practices carried 
out by biobanks are scarce. For example, some of our inter-
viewees expressed that privacy issues are not something to 
worry about. The main reasons given are that the data is not 
sensitive and that the security system is difficult to break. 
Still, one of the objectives mentioned included to not have 
any complaints from donors. One strategy to achieve this 
is to not interact directly with donors and leave that part 
to clinicians. For the biobank, that makes it much easier to 
preserve the identity of the patient and avoid privacy is-
sues. So, in this case, the engagement is delegated to ac-
tors that are often external to the biobank. Still, interest was 
expressed in having donors and general society know what 
biobanks are, what their objectives are and how informed 
consent works. However, some of the biobanks admit that 
they have not done much to achieve this objective. Some 
planned strategies to engage donors, which would include 
making leaflets for waiting rooms in clinics, using media to 
reach them or having a website.
In general, engagement in Spain is an ongoing process. 
With most stakeholders, the process is still in a very young 
state, very far from reaching any sort of stability and, still 
further from achieving sustainability. Nevertheless, there is 
a strong conscience about it and the efforts to develop are 
as big as time and resources allow. There is a lot to be done 
but there seems to be the will to do it.
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Background and history of biobanking
In the UK, donation has traditionally been seen as a na-
tional altruistic practice. This vision, according to Busby 
(2006, 851), is a “distorted and highly truncated reading 
of Titmuss”, which prioritizes the individualistic merit in-
stead of a systemic one. According to Busby, such vision 
has also rendered antiquated in front of the irruption of 
new technologies as it does not fit very well with the new 
approaches to biobanking incarnated by projects such as 
the UK Biobank.
As Zika et al. (2010) explain, the UK has a strong pub-
licly funded healthcare system which has potentiated the 
expansion of the biobanking sector in the country. Most 
such biobanks are small, but we can also find some larger 
projects. Some examples are Generation Scotland, the EPIC 
project on cancer and nutrition, the UK Women’s Heart 
Study or the Twin Research Unit Laboratory. An espe-
cially interesting project is the UK DNA Banking Network 
(UDBN), funded by the MRC, and based in the University 
of Manchester. This is not so much a research project, but a 
biobanking infrastructure trying to offer scientists “a mod-
ern and efficient infrastructure for management of samples 
and data” (Zika et al. 2010, 53). Links are created between 
databases holding samples and data while the custodian-
ship remains with the collectors.
United Kingdom
Sample storage. Image credit: Aaro Tupasela
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The history of biobanking in the UK is closely tied to 
the development of the UK Biobank which is the largest 
biobank in the country, and also one of the biggest in the 
world. This project has heavily conditioned the develop-
ment of the biobanking sector in the UK. Of course, the 
biobanking scene existed before and smaller biobanks 
remain active and do a lot of work. Nevertheless, the en-
trance on scene of the UK Biobank significantly boosted the 
biobanking sector. The main result is that the topic started 
to get massive attention from social researchers and media. 
UK Biobank became integrated in the existing biobanking 
structure by filling a role that did not exist before. While 
smaller biobanks keep a narrower focus and are usually 
tied to hospitals or focused on specific diseases, the UK 
Biobank has a much broader focus, trying to cover an im-
mense ground of biomedical research related to common 
diseases. The funding for the project was allocated in 2002, 
although the first stages towards the project happened in 
1998, when the MRC received extra funding to establish a 
DNA collection (Busby 2006). The funding which came from 
the MRC, a government body, was combined with addition-
al funding coming from the Wellcome Trust, a charity. Both 
institutions started conversations to develop a joint project 
in 1999 (Peterson 2005) and now have the responsibility for 
the direction of the biobank, while they receive advice from 
the Ethics and Governance Council, established expressly 
for the project. The combination of a public institution and 
a charity makes an interesting combination that conditions 
the main aims of the biobank. The first recruitment phase 
started in 2006. In 2012 the data and the samples started to 
be available for researchers under the condition that results 
needed to be made public, although not necessarily in an 
open access journal (Watts 2012).
There is also a private biobanking sector in UK, which is 
mainly associated to pharmaceutical companies. Although 
their collections are proprietary, it is difficult to gather in-
formation about them (Zika et al. 2010, 55; see also Lewis 
2004). It is also worth mentioning the UK Cord Blood Bank 
which is a private enterprise that gives service to parents 
accross Europe wanting to store cord blood samples of their 
newborns. In this case, the parents retain proprietary rights 
on the samples. Because of ownership issues, research re-
mains a marginal part of the company.
The UK has also had a very heated public debate on 
the ethical issues and consequences of research with hu-
man biological samples. A great part of the debate has been 
stirred by GeneWatch UK, a stakeholder group interested 
in the development of genetic technology. The group has 
accused UK Biobank of being based in false assumptions 
and of being a waste of public money (GeneWatch 2006). 
Some of the main issues raised by GeneWatch represent 
doubts about privacy and the use of samples and data for 
commercial purposes. To counteract these criticisms, one of 
the main strategies of UK Biobank has been the creation of 
public debate with different types of stakeholders (citizens, 
researchers, scientists, clinicians, industry, etc.) so all the in-
terested parties get the chance to comment on the project. 
Also, the creation of the Ethical and Governance Council 
has been an attempt at responding to the criticisms. Public 
consultations were considered by some stakeholders as a 
“bolt-on activity to secure widespread support for the pro-
ject rather than a genuine attempt to build a consensus on 
the project’s aims and methods” (House of Commons Se-
lect Committee on Science and Technology 2003, 7, cited 
in Petersen 2005)
Legislation
In November 2004, the Human Tissue Act (HTA) was 
passed as a law but it would not come into force until 
the 1st of September of 2006. This Act meant “a compro-
mise between the government’s desire to put patients’ 
consent at the heart of the legislation and the research 
lobby’s requirements” (Busby 2006, 856). It was an answer 
to the previous law on the removal, retention, and use of 
human tissue, which contained many uncertainties (Zika 
et al. 2010). The new law was also highly motivated by a 
series of scandals about organ-retention in some hospi-
tals of the UK. This made evident that the old regulations 
were not useful anymore. The enactment of the act es-
tablished the Human Tissue Authority in the UK, which 
regulates research/medical use tissue banks. The Human 
Tissue Authority (HTA) was established under the HT Act 
and is sponsored by the Department of Health. This same 
authority has the responsibility of issuing licenses for re-
search with human biological samples. The HTA needs to 
be seen in combination with the Data Protection Act, from 
1998, which regulates privacy and data protection issues 
in the UK. This act is the application of the EU Directive 
95/46/EC that deals with the protection of individuals and 
the processing of their personal data as well as the free 
movement of such data (Zika et al. 2010, 58). The HTA itself 
states that its main aim is “to set standards that are clear 
and reasonable, and in which both the public and profes-
sionals can have confidence”5. 
5 See http://www.hta.gov.uk/aboutus.cfm
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So one of the first standards that need to be set is what 
type of material is considered “human tissue”. For HTA this is 
“defined as material that has come from a human body and 
consists of, or includes, human cells”6. The basic definition 
of what is “relevant material” for the Human Tissue Act can 
be found in the Section 53:
1. In this Act, “relevant material” means material, other
than gametes, which consists of or includes human cells.
2. In this Act, references to relevant material from a human 
body do not include:
a. embryos outside the human body, or
b. hair and nail from the body of a living person.
This relevant material is then divided into four different 
categories:
1. Cell deposits and tissue sections on microscope slides
(as they will probably contain whole cells)
2. Specifically identified relevant material
3. Processed material
4. Bodily waste products (including excretions and secre-
tions)
As these definitions may be confusing, the HTA offers a list 
on its website with more specific examples of what “rel-
evant material” is7.
In the new law, informed consent becomes the funda-
mental principle behind its composition. According to the 
Act, consent needs to be given voluntarily, can only come 
from a person who has been properly informed and with 
the capacity to agree to the activity of donation. Having 
any human tissue, with the intention of its DNA being ana-
lysed and without the proper informed consent, it is con-
sidered an offence according to the Human Tissue Act. In 
the guide about informed consent issued by the HTA, they 
state that “appropriate consent is defined in terms of the 
person who may give consent. This is either the consent of 
the person concerned, their nominated representative or 
(in the absence of either of these) the consent of a person 
in a ‘qualifying relationship’ with them immediately before 
they died” (Human tissue Authority 2014, 8). The duration 
of the consent may be variable as expressed in the articles 
37 and 38 of the Code of Practice. The donors have the ca-
pacity of setting a time limit or withdrawing their consent 
any given time. It is also advised to discuss this issue in the 
outset of the consent relationship.
The Law applies to England, Wales and Northern Ire-
land, while Scotland has its own Human Tissue Act, which 
was passed on 2006 and derives heavily in all its provisions 
from the one covering the rest of the United Kingdom.
Engagement practices and social aspects 
related to biobanking
Engagement was considered an essential activity for our in-
terviewees in the UK. According to them, the sustainability 
of biobanks, the quality and amount of their samples, the 
funding, their capacity to produce good research, depends 
on their ability to engage with other social actors. In our in-
terviews we have two examples, which represent individual 
biobanks and network biobanks. From the first category, we 
have the UK Biobank, which stands as the main example 
of a big and global biobank, and from the latter one, we 
have the Confederation of Cancer Biobanks (CCB) which is a 
network that allows smaller biobanks to be associated and 
facilitates collaboration.
In that sense, the first thing we noticed in our inter-
views is a tendency in biobanks to associate and collaborate 
with each other in the form of networks. These initiatives 
include often smaller biobanks, especially at the national 
level. Being part of a network from the beginning repre-
sents some an advantage as original members are able to 
give shape to the network so they do not need to adapt 
later on, which is what new members need to do, having 
sometimes difficulties to do so. Therefore, not all biobanks 
engage in the same way with the networks they belong to.
But UK seems to lack a proper national coordination 
body. While there are several biobank networks, these are 
usually focused on specific diseases (e.g. cancer). Such na-
tional coordination center, planned by the MRC, will also 
help in terms of global engagement, as it will act as the 
node for interaction with European structures such as the 
BBMRI-ERIC. The center would do similar tasks to those 
smaller disease based-networks and some of those as, for 
example, the CCB, could be absorbed by it.
One of the main advantages of belonging to a net-
work springs from the possibility of cooperation. Commu-
nication and sharing of samples between biobanks is fa-
cilitated by a network infrastructure. Still, many biobanks 
are reticent to fully participate. The main issue is that net-
works make them more public, which is, in principle good, 
but presents a higher risk in terms of privacy due to is-
sues related to the sharing of samples. This makes it more 
difficult for researchers to find proper samples for their 
projects. Because the main aim of a biobank network is 
to increase visibility, refusal to share would prevent them 
from joining the network.
It is because of this reason that networks usually have 
a set of standards that regulate and evaluate the activity of 
the members and the access of new ones. But not only that, 
6 See http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/legislation/humantissueact.cfm
7 List available at http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/definitionofrelevantmaterial/
listofmaterialsconsideredtoberelevantmaterialunderthehumantissueact2004.cfm
27
also developing the standards is an activity that creates en-
gagement and collaboration between biobanks as they 
work together to develop the standards. Standards also 
determine which biobanks will be part of the network. One 
of the challenges when developing them was to set them 
at the proper level. Setting the bar too high would leave 
many growing biobanks out while setting it up too low 
would make the biobank unattractive for more developed 
biobanks. Therefore, homogeneity in the working method 
among biobanks makes it easier for them to collaborate 
and to fulfill the potential needs of collection users. If the 
members do not share the same standards, it is easy to find 
more difficulties. But heterogeneity also has benefits. Hav-
ing more experienced biobanks makes it much easier for 
smaller biobanks to develop and learn from them, further 
contributing to the development of the general biobanking 
scene of the country.
A large part of the know-how which helps to develop a 
good sample collection will also help engage with research-
ers. The success of a project is measured not only in terms 
of samples collected, but also in terms of samples used. It 
is at this point that engagement with scientists becomes 
especially relevant. The more the data is used and then sent 
back to the biobank, the more valuable the resource be-
come. In addition, the more valuable the data is, the more 
researchers will want to use it. Because of this, it is impor-
tant also that researchers acknowledge in their papers the 
contribution of the biobank, although this task seems not 
to be especially easy.
Another way of making data more valuable is by 
strengthening the interoperability between biobanks, so 
samples from different biobanks can be combined. One 
of the facilitations strategies in the CCB is a shared sample 
database. There, biobanks would make public their collec-
tions and other biobanks could find them and request them 
in case of need. Nevertheless, this is not easy as biobanks 
seems reticent to use this system.
But engagement between biobanks and researchers 
is not only beneficial for the biobanks. Being associated 
with a good biobank network with high standards may be 
useful for researchers when they are looking for funding. 
Therefore, developing high quality standards can also help 
to engage more researchers. Finally, another strategy to 
make data more valuable and, therefore, to engage more 
scientists, is to improve its quality through what is called 
“enhancements to the project”. Incorporating more data 
from the same person and linking it to the previous data 
will increase the value of the resource. Re-engagement with 
donors seems to attract more resarchers therefore turning 
into an mediated engagement strategy. 
Engagement with donors, as it has been mentioned 
several times before, has been one of the main worries for 
the biobanking sector. It seems that, because of the histori-
cal background of biobanking in the UK, they have a much 
more prominent position than in other countries. This may 
be because of the notable role played by charities and pa-
tients’ associations in the UK. The objective of engaging 
patients and donors is quite clear: to get samples. Never-
theless, this task can often be difficult. As put by one of our 
interviewees, part of their task is “to capitalise on this good-
will and try and creat this (club type) feeling” (Interviewee, 
2013). In order to do this, biobanks need to identify donor 
motivations, which seem to be a rather hard task:
But if we could bottle what motivates them, gosh. You’d have 
something you could sell for a million dollars, because actu-
ally, it is slightly different in everybody. Which is, there is that 
sense of.. of giving back, I think a lot of people, too. A lot of 
people said about having been treated, and feeling that they 
ought to, give something back. (Interviewee, 2013)
One of the main motivations for a donor to engage is 
her/his connection to a certain disease. It seems that if one 
self or someone close has suffered from a disease, the mo-
tivation to collaborate would be higher. But even in those 
cases, automatic engagement is rather rare, it is necessary 
to go and get them. Websites, E-mails or traditional mail are 
the most common way to get in touch with people. But the 
balance between too much and enough information is also 
important. Donors do not want to know every detail, but it 
is useful that they know that things are proceeding (Snell 
et al. 2012). New technologies provide, not only a possible 
tool for engagement, but a compulsory one. More tradition-
al engagement strategies include community meetings, 
where interactive activities with donors are carried out or 
posters hung in clinics in order to raise awareness. How-
ever, engagement with patients and donors is not only uni-
directional, in the sense that the biobank emits information 
that may reach the public or not. A number of governance 
bodies in biobanks usually include at least one lay member, 
who takes part in all the decisions concerning the biobank.
All these strategies have two main objectives. One, as 
we have mentioned before, is to increase the motivation to 
donate. The second one is trust:
We need to be trustworthy. We can’t afford to cock up. We 
can’t afford to mess up, we can’t afford to lose data. Because 
then we will lose participant trust. And the thing that we 
have, and we constantly remind ourselves, currently, is 
that trust. That’s why we go to great lengths to respond 
to correspondence. I see a lot of correspondence. We write 
to people. I’ve written to thousands and thousands of par-
ticipants about, their worries or concerns or, their support. 
(Interviewee, 2013)
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There is a strong feeling that trust is a delicate thing. 
Any faux pas and all the effort to keep donors and patients 
engaged could go to waste. Without trust, donors will not 
come and, with loss of trust, donors will not stay engaged 
(Tarkkala et al. 2015). 
In this sense, it is also useful for biobanks to keep a 
good image through the media which, for example, has 
played a very big role in the development of the UK Biobank 
public image. Their role is that of secondary engagement 
agent, i.e. there is no final goal in engaging with media, but 
engaging with them allows biobanks to engage with other 
communities, especially with the public. The use of media 
allows mass engagement. The information is released to 
different agents and it is hoped that it will reach the target 
group but, still, it offers the possibility of reaching groups 
which were not thought to be important, but will still play 
a role in the development of biobanks. When our interview-
ees talk about media, they refer to quite a broad range of 
actors: television, radio, newspapers, websites, social net-
works or newsletters are some of the examples. Carrying 
out a successful engagement strategy with media was seen 
to facilitate the engagement with other stakeholders when 
approached directly.
Other stakeholders often relevant to biobanks are pri-
vate companies. Contrary to what happens with public en-
gagement, national policies rarely regulate the interaction 
between genetic research institutes and the private sector 
(Kerr 2003; Busby 2006). This is also the case in the biobank-
ing sector. Still, even if policies do not often acknowledge 
this relationship, biobankers find it not only as something 
necessary but actually unavoidable. According to one of our 
interviewees, it is usual that people in academia have con-
nection with industry. Therefore, this makes trying “to dis-
entangle” those connections “in a piece of research” rather 
hard. But this does not need to be something negative as, 
in the end, what biobanks want to do is make the resource 
usable and not to waste “time or money with lawyers. Or 
trying to disentangle relationships and costs” (Interviewee, 
2013). In this context, the public (here represented by aca-
demia) and the private collaboration are understood as one 
entity. This is not because they are the same kind of organi-
zation, but because by doing this, the complex landscape 
of engagement relationships with so many different stake-
holders is simplified. By dealing with two different types of 
stakeholders as if they were one, the process is made sim-
pler for biobank administrations.
In terms of funding, charities have historically played a 
central role in the history of biobanking in the UK. But en-
gaging with charities not only brings funding to biobank-
ing. Some of those charities focus on specific diseases and 
they tend to have their own researchers that are able to 
use the samples. Finally, being associated to a charity gives 
good commercial image to the biobank, as charities often 
have a good reputation.
Funding concerns always redirect to the common 
problem of sustainability, as we have seen already through-
out the report. Usually, funding for biobanks is directed at 
covering a certain period of time. Even if there is no reason 
for the funding to stop, there is always some uncertainty. 
Given the fact that they mainly deal with public entities, it 
is hard to say what are the costs and benefits and often, the 
latter ones, have an intangible form. It is hoped, neverthe-
less, that the cost of activities, such as storing or retrieving 
samples, will become lower in the future. This should help 
biobanks to become sustainable without having to rely on 
public funding. Even if then it becomes relatively difficult 
to develop long term plans in the biobanking sector, it is 
necessary for biobanks to think of a business and a sustain-
ability plan when founding a biobank. If the sustainability 
plan does not work efficiently, this may lead to the termina-
tion of a project.
A successful future in terms of sustainability necessarily 
passes through engaging with the international commu-
nity. Biobanks in the UK look at Europe as an opportunity 
for European biobanks to collaborate and grow together, to 
become more competitive through collaboration. Engag-
ing in international ventures will make samples and data 
more powerful, which will give the chance to have bigger 
numbers, better analyses and study rarer conditions. The 
international biobanking scene should have a collabora-
tive character instead of a competitive one. But globality 
also entails certain problems. It is difficult to coordinate 
networks that are horizontal and vertical. Therefore, some-
times it is difficult for biobanks to find their place in these 
international networks and establish upon whom to rely on 
a certain coordination responsibility. Also, keeping a local 
or even national entity connected and active in the interna-
tional community has a cost in terms of time and resources. 
Sometimes, given the small size of many biobanks in terms 
of staff, they do not have the time to carry out their daily 
duties and engage in international ventures.
Biobanks in the UK seem to be well positioned in terms 
of engagement. They usually have good relationships with 
charities and public administration. This seems to give them 
some stability and also independency from private inter-
ests. They carry public engagement events when possible 
and tend to have lay people inside governmental boards. It 
is not a surprise that being one of the leading countries in 
biobanking also entails a successful and efficient engage-
ment strategy.
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Background and history of biobanking 
The inclusion of the US in this report is based on a num-
ber of factors which make it of significance for a broader 
analysis and understanding of global biobanking, engage-
ment and sustainability. Some have argued that much of 
the European knowledge-based bio-economy (KBBE) and 
sustainability policy discourse is based on the develop-
ments that took place in the US in relation to biotechnol-
ogy (cf. European Commission 2005). As Gottweis (1998, 
157) has noted, “the idea that the industrial application of 
genetic engineering would lead to the establishment of a 
new industry, the biotech industry, was born in the United 
States.” Although Europe developed similar biotechnology 
engineering programs dating back to the 1980s it is not un-
til after the turn of the millenium that biobanks begin the 
gain momentum as an organizing principle in the US and 
Europe on the policy level. In addition, much of the discus-
sions surrounding commercialisation of academic research 
stems from developments that took place in the US during 
the 1980 (Boyle 1996). Within this context, the role of tissue 
collections, the acquisition, storage and distribution has 
come to play an important role for the development and 
expectations associated with biomedical research in the US, 
and subsequently elsewhere.
Although the use of human tissue in biomedical re-
search is not in itself new, some commentators have ar-
gued that recent biomedical research practices using tis-
sue sample collections constitute a new object of study 
within biomedical research (Strong 2000). The US Navy, for 
example, developed one of its first tissue banks in 1949 to 
help orthopaedic surgery during that period (Strong 2000) 
and several commentators have noted that some institu-
tions have archived specimens that are more than 100 years 
old (Eisemann and Haga 1999). Despite their long history 
in the US, and elsewhere, the recent push to harness the 
contents of biobanks into translational research has placed 
increased attention on their role in biomedical research. It is 
not until the late 1990s that interests in biobankings begin 
to emerge in the US in any systematic fashion. 
One study has suggested that by the turn of the mil-
lenium there were approximately over 300 million bio-
specimens in the US in both public and private institutions 
(Eisemann and Haga 1999). According to Maschke (2008, 
12), due to the lack of comprehensive regulations in the 
US concerning the collection, storage and use of tissue 
samples, there is a confusion about the application and in-
terpretations regarding the laws on research with humans 
in relation to biospecimens and related data. As a conse-
quence, there has emerged a large body of literature in the 
US in relation to responsible research and best practices 
regarding biobanking (see National Cancer Institute 2007). 
In addition, there have been a number of landmark court 
cases in which the rights of patients and research subjects 
have been tested in relation to the use of said samples and 
information (Hardcastle 2007; Boyle 1996).
In their organisational study of US biobanks, Boyer et 
al. (2012, 511) identified five general types of biobanks: 
commercial biobanks, university-based collections, small 
collections created by individuals or groups, government 
funded or facilitated collections, and non-profit disease ad-
vocacy organisations. Noting that since there is no common 
definition of what a biobank is, the possibilities of survey-
ing them can be challenging. Despite these limitations they 
identified 624 biobanks that operated in the US.
A major feature underlining the legitimacy and 
sustainability of biobanking in the US and concomitant 
biomedical research rests, however, on the importance 
of community engagement in relation to population re-
search in general. The history of medical research in the 
US, particularly as it applies to minorities and vulnerable 
populations has been marked by major controversies in 
which individuals and whole groups of people have been 
mistreated in the course of medical research. Although 
falling under the more general category of medical re-
search, as opposed to biobanking specifically, the expe-
riences and outcomes of the investigations into these 
wrongdoings have provided heightened attention to the 
conditions and regulatory framings in which biobanking 
in the US operates today. Another salient feature of the 
US market in bodily tissues relates to its strong empha-
sis on free markets and the private commercial sector in 
pushing development (Schepher-Hughes and Wacquant 
2002).
USA
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Legislation
Although there is no specific set of legislations governing 
biobanks in the US, the activities related to biobanking and 
research are governed by a set of laws on related matters 
such as medical research, informed consent (Deschenes et 
al. 2001), privacy, (OHRP 2004; Lin et al. 2004; Annas et al. 
1995) as well as guidelines concerning the collection and 
use of biological materials (NBAC 1999). There are a num-
ber of Acts that have significant bearing on the way genetic 
information may be used, such as The Genetic Privacy and 
Nondiscrimination Act of 1995 (S. 1416 and H.R. 2690, as 
well as The Medical Records Confidentiality Act of 1995 (S. 
1360). In addition a number of organisations have drafted 
documents which provide guidelines for those conducting 
research using human tissue samples, such as the Ethical, 
Legal and Social Implications Working Group of the Nation-
al Center for Human Genome Research (Grizzle et al. 1999; 
Clayton et al. 1995).
A major guiding document in the US has been the 
Belmont Report (1979) which “is a statement of basic ethi-
cal principles and guidelines that should assist in resolving 
the ethical problems that surround the conduct of research 
with human subjects.” The report is the outcome of the the 
National Research Act (Pub. L. 93-348) which was signed 
into law in 1974 which called for the setting up of National 
Commission for the Protection of Human Subjects of Bio-
medical and Behavioral Research. This commission was 
charged with exploring various ethical issues, which re-
lated to research on human subjects and one of its earliest 
major contributions to this area was the publication of the 
Belmont Report. 
The regulation of the biomedical collection, storage 
and use of tissue samples in the US is confounded in many 
ways by the fact that practices are governed and judged 
at both the state and federal levels. In relation to the bio-
medical use of human tissue sample collections, there has 
emerged a large body of literature and case law in the US 
that has explored the role of patients, as well as citizens and 
their rights over samples that have been taken from them 
(cf. Boyle 1996). As a result, much of the practices, interpre-
tations and understanding in the US related to biobanking 
and biomedical research using human tissue samples is 
based on cases in which the merits of various positions are 
argued through the court system; first at the state level and 
then through the appeals process which can ultimately lead 
to the federal level. In the following we will cover some of 
the major cases that have taken place in the US that have a 
bearing on biobanking practices either indirectly or directly 
in the US.
Moore v Regents of the University of California
The case of John Moore, who began treatment for his leu-
kaemia in 1976 at the University of California Medical Cent-
er, has been one such landmark case. The doctors treating 
Moore realized very early on that his particular type of leu-
kaemia and the products that they could produce resulting 
from it were commercially very valuable. Over the years that 
Moore received treatment, his doctors collected numerous 
tissue samples from his body including the removal of his 
spleen. In 1981 the doctors were able to establish a cell line 
and consequently the University of California proceeded to 
patent Moore’s T-lymphocytes, whereby his doctors were 
listed as inventors (see Boyle 1996, 22). Moore felt that he 
had certain rights to the samples that had been removed 
from him and proceeded to take legal action against the 
university.
The significance of the case is reflected in the ensu-
ing US Supreme Court decision whereby it was ruled that 
Moore did not have property rights in the cells and genetic 
information that had been removed from his body. The 
court argued, among other things, that by agreeing to take 
part in treatment and provide samples, Moore had ‘aban-
doned’ his cells. Another major argument put forward by 
the courts was that the provision of property rights in bod-
ily fragments would in due course hinder scientific research 
in such a way that it would become prohibitively expensive 
in the future (see Moore v. The Regents of the University of 
California 1990).
Greenberg v Miami Children’s Hospital
The case in question involved the parents of a child affected 
by a rare disease called Canavan disease and the research-
ers and hospital which were involved in finding the genetic 
causes behind the conditions and subsequent development 
of a genetic test. The parents had been very active in finding 
other families affected by the condition and then recruit-
ing them to participate in the research by donating familial 
information and samples so that a test could be developed. 
With the assistance of the parents the researchers were able 
to identify the gene associated with the condition and sub-
sequently sought to patent it and restrict access to it. 
The parents felt that the doctor and the hospital had 
breached their agreement by patenting the mutation and 
restricting access to it by others, a goal which the parents 
had held as crucial to their recruitment of other parents and 
acquisition of research funding. Following the Moore case 
The Federal District Court of Florida ruled that the donors 
had no property rights once donation had occurred (Hard-
castle 2007). The ruling drew heavily on the language and 
arguments that had been laid out in the Supreme Court 
decision made concerning Moore and his cells. Although 
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the case did not go further in the US court system due to 
an out of court settlement, it also highlights the legal status 
of tissue sample in the US once they have been donated.
Washington University v Catalona
The final case we want to highlight relates to the legal sta-
tus and ownership rights of Washington University and 
the GU Biorepository collection which had been built and 
developed to study prostate cancer. The GU Biorepository 
had samples from approximately 30 000 research partici-
pants who had been enrolled in medical research and who 
were referred to as ‘research participants’. The doctor who 
had been most involved in setting up the collection and 
had been involved in the treatment of many of the patients 
moved to a new position at a different hospital and con-
tacted the research participants for permission to transfer 
their samples to the new institution; over 6000 of the par-
ticipants consented to this. Washington University objected 
to this noting that they had property rights to the collection 
and that the research participants could not decide how the 
samples would be used and whether the rights could be 
transferred to another institution (Hardcastle 2007). In the 
ruling the judge ruled in favour of Washington University 
noting that if participants could move their samples from 
one institution to another the integrity of biorepositories 
would be in serious peril.
Although the first two cases above relate to issues of 
ownership relating to human tissue samples and subse-
quent research, and not specifically to biobanking per se, 
the court cases highlight the process through which rights 
and duties are negotiated within the US system, as well as 
the values and expectations that are assigned to research-
ers and research participants when samples are procured 
through donation.
Engagement practices and social aspects 
related to biobanking 
As mentioned above, although there is no set of specific 
legislation governing biobanking in the US, there none-
theless exists a number of policy documents and general 
guidelines on a multitude of issues which provide ethi-
cal guidelines and frameworks for operations related to 
biobanking, such as informed consent. In relation to the 
notion of engagement, which we have been exploring in 
relation to biobanking a seminal text is the text “Principles 
of Community Engagement” (CDC 2011) that was first pub-
lished by the Centers for Disease Control in 1997. Accord-
ing to the CDC, community engagement is grounded in 
the principles of community organization: fairness, justice, 
empowerment, participation, and self-determination.
According to the CDC the principles of community en-
gagement are founded upon,
…the process of working collaboratively with and through 
groups of people affiliated by geographic proximity, special 
interest, or similar situations to address issues affecting the 
well-being of those people It is a powerful vehicle for bring-
ing about environmental and behavioral changes that will 
improve the health of the community and its members It 
often involves partnerships and coalitions that help mobi-
lize resources and influence systems, change relationships 
among partners, and serve as catalysts for changing poli-
cies, programs, and practices. (CDC 1997, 9)
The idea behind community engagement is that the 
uptake and success of interventions is based primarily on 
the social conditions in which interventions are imple-
mented and practiced. As a consequence it is believed 
that through community engagement the impact and 
benefits of any research and possible interventions will be 
greatly improved. A large number of surveys, focus groups 
and engagement activities have been performed in rela-
tion to many US biobanks to understand the expectations 
and motivations of biobank participants and their relatives 
(Kaufman et al. 2008; Halverson and Friedman Ross 2012; 
Brothers et al. 2011)
Much of the ideas surrounding community engage-
ment in medical research are an outcome of the sometime 
problematic experiences that many groups of people – es-
pecially minorities – have experienced at the hand of medi-
cal research in the US. Some examples of these include the 
Tuskeegee study of untreated syphilis in the black males 
where treatment was withheld from men who were afflict-
ed with syphilis (Epstein 2007). A similar study has come 
to light that took place in Guatemala between 1946 and 
1948 where US doctors deliberately infected people with 
sexually transmitted diseases. According to a US study on 
the issue “subjects were exposed to syphilis, gonorrhea, and 
chancroid, and included prisoners, soldiers from several 
parts of the army, patients in a state-run psychiatric hospi-
tal, and commercial sex workers” (Presidential Commission 
for the Study of Bioethical Issues 2011, 2). Such tragedies 
have led over the years towards policies which emphasise 
transparency, accountability, as well as ongoing community 
engagement with those communities that researchers have 
sought to study.
Putting aside the scandals that have helped to shape 
policies in the US that emphasise community engage-
ment, a number of recent developments surrounding the 
decreased costs of genomic tests need to be examined to 
understand some of the more important changes that have 
been taking place within the commercial sector. During the 
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past decade there have emerged a multitude of companies 
offering personal genetic testing services to consumers 
(Hogarth et al. 2008). Based on the idea that genetic tests 
are becoming more accurate and information and under-
standing about the role and function in genes in predict-
ing disease has improved greatly, a number of commercial 
companies have sought to provide services to consumers 
who are interested in such services.
One of the most notable US-based companies has 
been 23andMe (www.23andme.com) which offers a genetic 
test that can be ordered online. Customers are sent a test kit 
where they are asked to provide a sample of saliva and send 
it back to the company. A few weeks later the customer will 
be notified of their test results, which they can view online. 
The service also provides a number of other services, such 
as genetic ancestry and drug response results, as well as 
the possibility of linking up with possible genetic relatives 
who have taken the test as well. The purpose of these on-
line tests is not to provide consumers with clinical tests or 
diagnostics, but rather the test is intended for research and 
educational purposes only (Lee 2013).
What makes the services provided by 23andMe of in-
terest is the style and form of engagement they articulate 
in attracting customers to purchase their services. Much of 
the online service is geared towards developing an online 
community through which customers can discuss ques-
tions, gain support and meet others who might have similar 
conditions. The site provides a similar experience to that of 
Patients like me (www.patientslikeme.com) which provides 
an online peer support network for people who are seek-
ing support from others with the same medical conditions 
as themselves. Recently, however, the FDA has prevented 
23andMe from continuing to provide its services under its 
current remit, noting that its services are considered diag-
nostic in nature, but the validity of their findings have not 
been sufficiently validated. The FDA has been concerned 
that the consumer is being mislead as to the trustworthi-
ness of the information. Interestingly, 23AndMe has simply 
moved its service provisions to other countries where the 
regulatory landscape has not yet prevented it from offering 
its services.
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Background and history of biobanking
Finland has a long tradition in collecting biological samples 
and connected lifestyle and health information for research 
purposes. Large collections from population research done 
at the National Institute of Health and Welfare (THL), diag-
nostics samples in hospitals, and samples from different re-
search projects conducted at the universities form a basis 
of Finnish tissue collections. The Finnish biobanking sector 
has been regarded as a national asset because of these long 
traditions, and also because of a relatively homogeneous 
population, positive attitudes towards science, possibilities 
in combining register data and the existence of personal 
social security number (Carpén and Launis 2014, Kallion-
iemi et al. 1020).
Finland has been conducting research into national 
health risk factors since the 1950s and collecting DNA-
samples for such purposes since the beginning of 1980s 
(Aromaa et al. 2002, 7; see also Anttonen et al. 2004). The 
research has produced a wealth of tissue samples in differ-
ent form, as well as important information on health risks 
in the Finnish population. In the European context, Finn-
ish collections have gained importance in that they are of 
high standard and have been conducted on a number of 
important common diseases, such as diabetes and heart 
disease and that unlike more notable efforts, such as the 
UK Biobank, these collections already exist and have been 
followed meticulously over the years through longitudinal 
studies, especially at the National Institute of Health and 
Welfare.
Finland
Automated sample handling and processing. Photo credit: Aaro Tupasela
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According to a study in 2004 funded by the Finnish 
National Technology Agency Tekes, Finland had over 190 
000 samples within ten of its most significant epidemiologi-
cal cohort studies (Technomedicum 2004). This represents 
about 3.6% of the country’s population, which in compari-
son to the UK Biobank’s 500 000 samples from a popula-
tion of over 60 million represents only under 1% sample 
of the population. According to the report, these samples 
and the related health information could be used far more 
efficiently in the study of the human genome, diseases, as 
well in the development of pharmaceuticals and treatment. 
The report also sees genome research as uniting science 
and industry in a way that will give Finland an edge over 
similar competing projects elsewhere in the world. In addi-
tion to the epidemiological cohort collections, Finland has 
pathology collections that amount to well over 2 million 
samples. These sample collections are used routinely in 
medical practice for teaching and research, as well as for 
comparative purposes if patients are re-diagnosed with a 
new condition. Together these sample collections are seen 
by both researchers and policy makers as a significant na-
tional resource that should be organised to facilitate the 
development of new innovations and scientific discoveries 
(see Academy of Finland 2003, TEM 2014). 
Some notable examples of important population 
based studies include Finrisk -97, -02, -07 and -12 that has 
looked especially at cardiovascular disease and is made up 
of over 15 000 samples with informed consent; the Finnish 
twin cohort study has over 170 000 samples of twin pairs 
and the Northern Finland cohort has 20 000 samples with 
informed consent. All studies include carefully documented 
lifestyle information that can be compared and utilised in 
new studies as well. The importance of these studies has 
increased in that, not only can they be used to study other 
diseases than what they were originally collected for, but 
they can also be combined with other similar studies to 
gain a larger population sample, either within Finland or 
internationally. 
Legislation
The last couple of years have, however, created a new situ-
ation for biobank research in Finland. A new Biobank Act 
(Act 688/2012) came to force in September 2013. The act 
is one of its kind in Europe as it regulates directly and only 
biobanks of all types – from population to clinical and dis-
ease based biobanks and public as well as private biobanks 
(Soini 2013). The Biobank Act defines criteria for biobanking 
and its passing has resulted in a situation where all research 
infrastructures that called themselves biobanks prior to the 
enactment of the Biobank Act have to apply for permit to 
function as a biobank as defined by the act. This has created 
lots of activities in the field and most old tissue collections 
will be or have already started the process of transferring 
to biobanks. 
The two first biobanks – as defined in the act – got their 
permissions to start operation in early 2014 from Valvira, 
the National Supervisory Authority for Health and Welfare 
that supervises biobanks. Before Valvira’s authorisation, the 
biobanks have to first get an ethical approval from TUKIJA, 
The National Committee on Medical Research Ethics. The 
first two new biobanks are Auria Biobank (a clinical biobank 
in the Turku area) and THL Biobank (a national population-
based biobank, to which it transfers its major longitudinal 
cohorts). Auria Biobank’s goal is to get new samples from 
every patient enrolled in the hospital. During the retrieval 
of a diagnostic sample a surplus sample will be given to the 
biobank after receiving consent from the patient. In addi-
tion it is transferring old sample collections of the hospitals 
as well as research project samples to the biobank. About 
80% of the samples in Auria Biobank are cancer samples. 
Other biobanks that have already gotten TUKIJA’s approval 
are Helsinki Urological Biobank (HUB) and Finnish Hematol-
ogy Register and Biobank (FHRB). These two biobanks are 
dedicated to specific disease groups (urological diseases 
and haematological diseases) and both have a strong ori-
entation towards combining research and care. Academic 
Medical Center Helsinki Biobank (AMCH) - which is a clini-
cal biobank of the Helsinki area - has submitted its applica-
tion to TUKIJA. AMCH differs from Auria, as it does not aim 
at such a comprehensive recruitment, but it is basically a 
similar clinical biobank that has close links to the local uni-
versity. HUB will be merged to AMCH in the future. It is im-
portant t note that changes in the biobank structures, host 
organisations and actors behind the biobanks can have a 
considerable effect on public opinion (Snell et al. 2012). In 
the planning stages there are at least four other biobanks 
located in different parts of Finland: Tampere, Kuopio, Cen-
tral Finland and Northern Finland. 
Another important player in Finnish biobanking is 
the BBMRI.fi network. The network is one of the daughter 
networks of the European BBMRI. The goal of the BBMRI.fi 
is to enhance cooperation between Finnish biobanks and 
linking them to their European counterparts. The network 
is also aiming at developing a cooperation and discussion 
forum between biobank actors, financiers, state administra-
tion and research subjects/citizens.
The new legislation is in many ways in key position in 
defining the functioning and future of Finnish biobanking. 
The Biobank Act had been in preparation already since 
2007, and was finally passed by the parliament in spring 
2013. Some of the arguments for drafting the Biobank Act 
were based on securing the use of samples by defining con-
sent practices, enhancing the quality of samples and mak-
ing the sample collections more attractive for commercial 
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use (Kere 2007). The drafting process was long and com-
plicated with two governments, disagreements with the 
content and a belief that the system was working already 
rather well (see Kääriäinen 2009).
We started with biobank issues rather late. We have a lot and 
only now the legislation is coming. In Sweden they have had 
for long. But we have a strong tradition in clinical research 
and these bio centres that have cooperated… long tradition 
in research in genetics, population samples in THL, lots of 
contacts… I think we are doing well even though we had a 
late start, because of the old working systems. (Interviewee, 
2013)
The passing of the act was received mainly positively 
by the actors involved with biobanking because this meant 
that they could finally proceed with biobanking activities 
without wondering whether their activities will comply 
with the legislation. Even though after the passing of the 
law the main question is how the act will be interpreted by 
biobanks and civil servants in Ministry of Social Affairs and 
Health and Valvira. Biobank staff interviewed described the 
situation:
Drama.. And here we don’t know at all how it will go, for ex-
ample what kind of decree it will be about the consent… 
But when the act was heavily criticised, we were the only 
ones that went to the Ministry and said that we don’t see 
any problems in it. (Interviewee, 2013)
We have got stuck in it, that first it took so long to get the 
act, and they assigned the steering group, and the working 
group of civil servants that should give the recommenda-
tions, the statues and possible recommendations. So we 
cannot do very much. We cannot say that let’s do this kind 
of consent forms because we have to wait that the working 
group would say what they will require. (Interviewee, 2013)
Not all were happy with the content and formulations 
in the act and how difficult the implementation period 
seemed to be. Many concrete parts of the act have received 
criticism (i.e. returning of research results, neglection of the 
idea of combining research and care), but the main target of 
disapproval was the complexity of the Act and uncertainty 
of how the Act should be interpreted. Some still questioned 
whether it is a relevant act at all – especially in relation to 
population and cohort based biobanks.
It is of course the act and how the act is interpreted. For ex-
ample how far the control of the consent goes for example. 
Can the person deny the use of his samples in an ongoing 
research project … (Interviewee, 2013)
When I looked at the first version [of the Act], and I said that 
we don’t need this kind of act at all. I thought it was totally 
unnecessary, and still almost do. It’s a kind of a “me too” leg-
islation. Because everyone else has a biobank act we had 
to have one too... But perhaps it is needed today. Because it 
seems that everyone is fixated on the idea that you can’t ask 
for a broad consent without that biobank act. And let it be 
so then. (Interviewee, 2013)
During the preparation process the act draft was com-
mented on two occasions (2007 and 2010) by the stake-
holders and finally also discussed in the parliament, but the 
law and biobanks in general have created very little public 
discussion. The enforcement of the Act and the establish-
ment of the first two biobanks have created some media 
attention though, which has been mainly positive. Some 
of the biobank actors have hailed the Act on Biobanks as 
the “best biobank law in the world” that enables research 
and secures the position of sample donors through wide 
consent and good control by the authorities. The act is also 
seen as a means to enhance public trust towards biobank-
ing.
And it [the Biobank Act] clearly, definitely increases trust 
because we have this legal frame and a specific model of 
operation that is being controlled. And it is good that there 
will be quality standards for specimen and information and 
of course information security and all… What is bad, is that 
the law is very complicated. (Interviewee, 2013)
Our study findings seem to suggest that the biobank-
ing community in Finland, draws a great deal of legitimacy 
and authority from official legislation in relation to their 
operations. Unlike the UK, where legitimacy and trust was 
drawn from extensive public consultation and engage-
ment, trust in Finland tends to operate through somewhat 
different channels.
Engagement practices and social aspects 
related to biobanking 
The Biobank Act serves also as an official basis for the en-
gagement practices of biobanks and has in many other re-
spects a large role in defining the governance of biobank 
research. The Act has some specific requirements for 
biobanks dealing with engagement of the public or donors, 
but it is worth to note that public engagement in the law 
is perceived more or less synonymous with informed con-
sent. The Act states that all biobank research is based on 
informed consent. The consent has been defined as wide 
but the participants can cancel their consent, or make re-
strictions to it.
The informed consent was seen as a cornerstone of 
biobanks also in our interviews. First, broad consent backed 
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by the legislation enables the operation of biobanks and 
the use of tissue samples and information. Without samples 
and related information, biobanking would not be possible. 
Second, it serves as a legitimation for action. If consent pro-
cedure has been done correctly, the samples and informa-
tion can be used for research purposes.
I personally think that if it is explained well and you go 
through the consent process, that it would be strange the 
something couldn’t be done. (Interviewee, 2013)
Third, consent can be perceived as a way to inform 
people about where they are possibly participating. A gen-
eral view among our interviewees was that Finnish people 
do usually give their consent and if the consent is clear 
enough and participation is made easy there are rarely any 
problems afterwards i.e. withdrawing the consent.
When the people show up, there is the question if they show 
up. so When they show up, they agree to almost anything. 
(Interviewee, 2013)
Consent can be seen as a form of contract for the use 
of participants’ samples and information. Sometimes it was 
also regarded as a possibility for face to-face contact that 
brings people closer to the research. This view was support-
ed by researchers who are heavily involved also in clinical 
work and encounter patients on weekly basis. They also 
tend to see participants more as stakeholders than people 
only involved with the research side of biobanks.
The act has been on one hand criticized by some be-
cause it focuses more on the operation logic of popula-
tion biobanks than on clinical or disease specific biobanks. 
On the other hand, the passage dealing with returning of 
research results is seen to be very problematic from the 
viewpoint of population or cohort biobanks. The act states 
that all biobank research is based on informed consent. 
The consent has been defined as broad but the partici-
pants can cancel their consent, or make restrictions it. The 
participants have according to the act also the right to get 
information about where their samples and information are 
being stored, where it has been gathered from and for what 
purposes they have been used and in addition the partici-
pants have a right to ask information determined about 
their health, and also the meaning of such information.
The insufficiency of informed consent as the only form 
of engagement or the suitable engagement for biobanking 
became also apparent. The consent model for biobanks is 
wide, and as it covers such a vast amount of research. Rely-
ing on consent can also weaken the other types of engage-
ment practices. Other actions are needed and the most 
prominent in Finnish interviews was the need for commu-
nication and public relations.
I have been thinking that as the consent is so broad and vague, 
we have to have, our operation ends that day when the trust of 
citizens runs out, or the willingness to support this activity. We 
have to communicate with them. We have to have this kind 
of active communications. (Interviewee, 2013)
The meaning is, it really is, that we have some person all 
the time at the end of a phone line. If for example people 
can take contact and ask whatever issues. And the aim is to 
transparently inform all the time, where we are going and 
what we are doing. (Interviewee, 2013)
One of the most notable ways of enhancing public 
acceptance or knowledge is seen to be good communica-
tion. Many of those interviewed stressed the importance of 
developing a communication strategy or otherwise being 
active in communication. Others pondered the timing of 
communication in order not to create too many expecta-
tions. The AMCH biobank has chosen not to be active in 
communication before it receives the final approval from 
Valvira to start the operation.
Auria has been forerunner in many issues. It has also 
been active in developing many types of communication 
and media schemes. They have hired a consultant firm 
to deal with public relations and communication. Auria 
Biobank has developed a game about biobanks to involve 
young people and has been active in arranging public lec-
tures about biobanking. They have also made a deal with 
Taltioni – a platform service provider – through which Au-
ria and the hospital district aim to communicate with the 
patients and biobank participants. Participants can follow 
through the service:
“how your biobanks samples are used in biobank research. 
You will receive information on the research of your sample, 
research results and on whther you can expect personal 
health benefots from the research” (www.auriabiopankki.fi)
This is in lain with the Biobank Act where it is stated 
that the participants have a right to ask information deter-
mined about their health, and also the meaning of such 
information. The Act was heavily criticized by some be-
cause it focuses more on the operation logic of population 
biobanks than on clinical or disease specific biobanks, but 
the passage dealing with returning of research results is 
seen to be very problematic from the viewpoint of popula-
tion or cohort biobanks. The passage transforms the one 
dimensional engagement of people that is visible in the 
other parts of the Act – providing samples and information 
to unspecified research that potentially benefits the popu-
lation as a whole – to engagement where personal informa-
tion to the participant should be provided on request of 
the participant. The criticism of returing research results to 
participants has been based on two main arguments. First, 
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population biobanks do not use clinical standards in their 
analysis. Therefore the results are not reliable from the view-
point of an individual. Second, population biobanks do not 
have a channel through which the information would be 
given to the individual. Interentingly, in the drafting process 
the Act was criticised particularly by those involved with 
disease based and clinical biobanks, because it was unclear 
whether the biobanks had a right to inform their partici-
pants (and in this case the patients) about their individual 
research results.
But the biobank law does not say that is will come back 
to care, instead in my opinion it prohibits it. It is a biobank 
as a biobank, they have thought about creating precondi-
tions for research… it has been seen as a closed bucket for 
research. (Interviewee, 2013)
Another aspect that has been heavily criticised in 
the Act on Biobanks, especially by hospital biobanks and 
biobanks aiming at translation of research result is that the 
Act does not take a strong enough stance on how to com-
bine research and care.
We are of course ready to bring the information to patients 
care. That has been the big problem that translational medi-
cine is trying to repair, that research and care are so far from 
each other at the moment. They should be brought closer to 
each other so that results can be used as fast as possible in 
patient care. (Interviewee, 2013)
The aspect of translation and how research and care 
can be combined has however become an acute polcy 
question for esample through the drafting of the national 
genome strategy. Engagement with different stakehold-
ers seems to be in many ways even more important than 
engagement with the public. This type of engagement is 
not discussed as much in the literature or in the web pages 
of the biobanks for example, but it is crucial for the opera-
tion of biobanks. Engagement of different stakeholders is 
extremely important especially in the phase where a new 
biobank is being constructed. For example Auria has al-
ready signed contracts with many industrial partners. Other 
important stakeholders include the regulatory authorities 
and other biobanks. The Finnish biobanks have been ac-
tively networking to form unifed standards and operation 
practices to ensure usability of samples and data. Especially 
in the establsishment of the new biobanks good connec-
tions to Valvira and TUKIJA – the regulatory authorities – 
have been essential. The relationships are also important in 
the phase were both the Biobank Act and biobank practices 
are being implemented.
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Background and history of biobanking
There are dozens of biobanks in Canada ranging from dis-
ease based to population biobanks. According to an es-
timate of Canadian Tumor Repository Network, there are 
about 10 000 collections of samples in Canada of which 
most are only for single purposes for only the use of one 
researcher or research group and around 80 large-scale 
biobanks with multiple users and uses of the data and 
samples (CTRNet 2013). Two of the most notable efforts in 
recent years have been in the field of population biobanks: 
the launching of Canadian Longitudinal Study of Ageing 
(CLSA) and Canadian Partnership for Tomorrow Project 
(CPTP). CLSA states its goal is “to mobilize experts in the 
community to generate the scientific content for a longi-
tudinal research platform that will enable interdisciplinary, 
population-based research and evidence-based decision-
making that will lead to better health and quality of life for 
Canadians.” There are currently about 50 000 participants in 
the Study with 30 000 participating in “CLSA Comprehen-
sive” where they provide more comprehensive health and 
lifestyle information and have the option also to donate a 
blood sample. Canadian Partnership for Tomorrow Project 
(CPTP) is a multimillion dollar research platform with cur-
rently almost 300 000 participants from different parts of 
Canada largely funded by the Canadian Partnership Against 
Cancer. The core of the platform is comprised of five region-
al biobanks: CARTaGENE (Quebec), Ontario Health Study 
(Ontario), Tomorrow Project (Alberta), Atlantic Path (Atlantic 
provinces), and BC Generations Project (British Columbia). 
In this report the main emphasis is on two of these: CARTa-
GENE and The Tomorrow Project.
CARTaGENE is a scientific project originally based at 
the Université de Montreal and then transferred to the CHU 
Sainte-Justine. CARTaGENE is composed of a health data-
base which is based on health and environmental ques-
tionnaires, a bank of biological samples (blood, urine and 
saliva) as well as range of physiological measures. There is 
also a genealogical database that is run by BALSAC project 
where people can participate in addition to the health re-
lated databases. CARTaGENE is a prospective health study 
where the research cohort has been targeted to the popula-
tion most at risk of developing chronic diseases: men and 
women of 40–69 years in Quebec. CARTaGENE defines its 
mission as follows: 
CARTaGENE’s mission is to create and maintain in the long 
term a bank of data and samples that represent the genomic 
identity of Quebec and are competitive on an international 
scale, thus facilitating the emergence of new research pro-
jects and knowledge regarding health care for Quebec, 
Canada, and the international community. 
(www.cartagene. qc.ca/en)
The participants are recruited from four metropolitan 
areas in order to facilitate translation into health promot-
ing policies and interventions. (Awadalla et al. 2012) CARTa-
GENE has received lots of attention in the literature as an 
example of a biobank project that has introduced engage-
ment of participants and the community into its operation. 
The engagement model has been labelled as “partnership 
approach” instead of “communication approach” adopted 
by many other biobanks (Godard et al. 2004).
The Tomorrow Project has been launched as a local 
study in Alberta in 2000 with aim of recruiting 30 000 par-
ticipants starting in 2002. In the study participants were 
recruited to fill in “pencil and paper” questionnaires and 
they also consented to getting a possible invitation to give 
a blood sample. From 2009 a new phase of recruiting has 
started in accordance with the launching of Canadian Part-
nership for Tomorrow Project - the Canadian wide biobank 
network. Currently there are 36 000 Albertans who have 
participated in the project. The Tomorrow project’s primary 
focus is on cancer research, but also on heart disease and 
other long-term health conditions.
... primary goal is to discover more about what causes can-
cer, so that it may be prevented in the future. 
(www.in4tomorrow.ca/)
The cohort consists of men and women of 35-69 years 
of age. In the current phase participants are asked to com-
plete health questionnaires and invited to consider pro-
viding urine, blood or saliva samples, and to have various 
physical measurements taken. Participants’ health will be 
tracked for up to 50 years through cancer registries and 
other health records.
The Canadian population is not homogenous, but has 
many different ethnic origins, therefore, the scope of cohorts 
is in many cases to achieve population representativity. Con-
siderable amounts of public funding both in the federal and 
Canada
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regional level have been made to biobanking and health re-
search infrastructures. This has enabled research projects such 
as the Tomorrow Project to transform into modern biobanks 
– although in Canada these kinds of infrastructures are rarely
called biobanks. In addition to significant funding, another 
success factor named for Canadian biobanks is the strongly 
supportive citizens who support both public health research 
and the public healthcare system (Caulfield et al. 2012).
Legislation
Canada has no specific federal law on biobanks. The regula-
tive framework varies also between the different provinces. 
The provinces themselves do not have direct regulation on 
biobanks but some of them have legislation dealing for ex-
ample with consent to research (Allen et al. 2013). The need 
for more specific biobank regulation both on the federal 
and on the provincial level has been argued for (i.e. Adviso-
ry group 2006). An important document that sets the ethi-
cal framework for biobank research is the Tri-council policy 
statement: Ethical conduct for Research involving humans 
(TCPS 2, 2010/2014). It is a document made by three prima-
ry federal funding agencies in Canada. Caulfield and Knop-
pers (2010) call it as the “de facto research ethics policy” in 
Canada. The document defines fore mostly the practices of 
informed consent. Most Canadian ethical guidelines pro-
pose rather strict requirements for consent, for example 
many of them argue for no secondary use without re-con-
sent (Allen et al. 2013) which is in contradiction to broad 
consent practices wanted and used by most biobanks.
Canadian law and ethics policies are built on a tradi-
tion of specific research projects and informed consent. 
But their application to biobanks is not clear (Caulfield and 
Knoppers 2010). Informed consent is a highly discussed 
topic in Canada and forms the bases for many ethical de-
bates. This fits well with the idea that autonomy and privacy 
are regarded as important values for Canadians (Caulfield 
2007). Canada has a rich legal tradition in the area of con-
sent and not with biobanks or even medical research have 
many examples in the Canadian consent case law. (Caulfield 
and Knoppers 2010). 
In addition to informed consent, guidelines for dis-
closure of incidental findings are formulated in the TCPS 
2 where it is stated that researchers have an obligation to 
disclose to the participant any material incidental findings 
discovered in the course of the research and an appropri-
ate plan is in place for managing information that may be 
revealed through their research. This passage has proven to 
be problematic as there are no guidelines to how to do this 
in practise. A Statement of Principles has been developed 
by a group of researchers from Quebec to bridge the gap 
between what is recommended in the TCPS 2 and the prac-
tical application (Sénécal et al. 2013). 
Because of the nature and quantity of the information ana-
lyzed, genetic or genomic research is especially likely to gen-
erate material individual results and material incidental find-
ings compared to other research domains. Consequently, in 
almost all cases, genetics researchers should develop a plan 
for managing this type of information. (Sénécal et al. 2013)
Still many Canadian biobanks, such as CARTaGENE and 
the Tomorrow Project were not disclosing any research re-
sults to the participants during the time of the interviews. 
The TCPS 2 was revised in 2014 and it introduced exceptions 
to the obligation to disclose material incidental findings. 
The return of research results is one of the key ethical, legal 
and practical issues currently in biobanking.
All and all, the ethical, legal and social (ELSI) questions 
of biobanking from the Canadian perspective have been 
relatively visible in Canada and internationally as some of 
the fields prominent experts come from Canada and have 
been working in cooperation with Canadian and interna-
tional biobank projects. The experts include such persons 
as Bartha M Knoppers and Timothy Caulfield. The Canadian 
ELSI research field has received ample funding and the ex-
perts have been publishing vast amount of publications. 
A notable part of Canadian ELSI research is funded by Ge-
nome Canada through the GE3LS initiative. The funding 
decisions and strategies have received also some criticism 
as it has been argued that only some big efforts lead by the 
established experts get funding and different opinions do 
not get heard. As a result of Canadian biobanking and ELSI 
efforts many best practices and guidelines have been de-
veloped through for example CARTaGENE and P3G, which is 
a Canadian led “international consortium dedicated to the 
development and management of a multi-disciplinary in-
frastructure that can compare and merge results from stud-
ies, biobanks, research databases and other similar health 
and social research infrastructures conducted around the 
world” (p3g.org).
Engagement practices and social aspects 
related to biobanking 
As stated before, Canadian biobanks such as CARTaGENE 
have been used as benchmark cases or examples of a “part-
nership approach” to engagement (Godard et al. 2004). This 
approach means that the public is not perceived only as do-
nors but as stakeholders who have opportunities to voice 
their opinions and perhaps even influence decision-making.
In fact, community consul tations are becoming an increas-
ingly common adjunct to genomics research. For instance, 
the UK Biobank as well as the Quebec Cartagene project 
adopted a “partnership approach” meant to involve the 
public in decision-making processes (Godard et al. 2010)
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Before the launching of CARTaGENE community 
consultations around Quebec were performed by market 
research organisations to identify the social and ethical 
concerns of the public by using focus group research. Also 
a phone survey among Quebecers was conducted. In ad-
dition, stakeholder consultations were arranged prior to 
the launching of CARTaGENE. Important stakeholders such 
as professionals in ethics, law, decision and policy-making 
were consulted. (Godard et al. 2010) 
There was some sort of public consultation before the begin-
ning of the project. But they had targeted selected groups of 
stakeholders and experts to sort of define the roles of the pro-
ject and the main objectives of the project. It wasn’t a public, 
it wasn’t open to the public per se. It wasn’t about only look-
ing at, that society in general was ready to accept the project 
with such a large public funding. (Interviewee, 2014)
Setting up a partnership model during the beginning 
phases of CARTaGENE may have been the goal and a strat-
egy adopted, but as a representative of CARTaGENE stated:
I have to say we haven’t been really strong at working with 
the community. So there’s not a big bridge between what 
we do and what the public has to say. (Interviewee, 2013)
The “partnership approach” has been part of the CART-
aGENE strategy, but practical work of biobanks, allocation 
of resources and transformations in the biobanking sector 
have transformed the focus and practices of engagement 
from public consultation to communication, mundane en-
counters and involvement of other stakeholders than the 
public. The prevailing mantra in biobanking has been to 
transform the donors as participants of biobanks. But the 
practical constraints and forms of biobank operation do not 
necessarily support this type of “partnership approach”. 
Both CARTaGENE and the Tomorrow Project have, how-
ever, used multiple methods of stakeholder and public en-
gagement. The main incentive for engaging the public has 
been to recruit participants. This has been primarily done 
by providing information to participants and potential par-
ticipants about the functioning of the biobanks and how 
one can participate in them. The biobanks have made press 
releases, posters, information leaflets and newsletters. And 
for example when the mobile study center of the Tomorrow 
Project arrives at a location in Alberta, the people from To-
morrow Project have been promoting their cause actively in 
local media. The media coverage of biobanks was regarded 
to be mainly positive in Canada.
They’ve [the media] been very supportive. I think we’ve used 
them mainly for public awareness. (Interviewee, 2014)
In addition to media, the Tomorrow Project uses also 
special ambassadors for recruitment.
We have also identified people, ambassadors, who are com-
mitted to the cause, to help to recruit participants. (Inter-
viewee, 2014)
The ambassadors give out leaflets in various happen-
ings, arrange “lunch and learns” and recruit friends and 
relatives to the Tomorrow Project. There are currently over 
800 ambassadors. This could be interpreted as some sort 
of one-way community involvement. Community involve-
ment is a form of engagement that has been acknowledged 
to be important also in Canada. There have been studies 
for example of how ethnocultural community leaders view 
biobanking activities. The leaders believed that biobanks 
could have positive impacts provided that their community 
members are not only informed but are also involved in de-
liberation, development and decision-making (Godard et al. 
2010). On the other hand the communal and social aspects 
of biobanking are used in the communication of biobanks 
to the public. In the communication material it is often re-
ferred to the willingness to help the community.
Many of the Albertans involved in our study have an innate de-
sire to help out in their community. (www.in4tomorrow.ca/)
I’m making a difference… for the future of my children. 
(www.cartagene.qc.ca/e)
In practice, the Canadian biobanks we have studied 
have not adopted strict community involvement as a form 
of engagement. It seems that in the beginning stages of 
CARTaGENE partnership model was promoted, but in real-
ity it has not been materialized but resembles more of the 
“communication approach”. Both biobanks under our scru-
tiny acknowledged that they could do more with public 
engagement. The Tomorrow project is planning to develop 
a participant engagement strategy and CARTaGENE is plan-
ning to build a communication platform to participants.
And what we’re going to try to do in the next year provided 
that we have funding, is try to develop somewhat of a plat-
form that would help us to have a good communication 
channel with our participants. (Interviewee, 2014)
It is interesting to note that in the article from 2004 
where Godard et al. promoted the partnership approach of 
CARTaGENE stated that “part three of the community con-
sultation plan consists of a deliberative electronic forum” 
which had not yet been developed in early 2014.
One of the reasons for not engaging more with the 
public is that Canadians in general have a positive attitude 
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towards research, genetics and biobanking (Caulfield et al. 
2012). Knopper’s has noted that the government officials 
were more apprehensive and critical towards biobanks than 
the people they represent. But one of the negative issues 
that have come about from the public is related to the return 
of individual research results. Even though the ethical guide-
lines by the TCPS 2 recommend the disclosure of material 
incidental findings most of the biobanks are not communi-
cating individual result back to the participants. 
One of the expectations we need to manage is that people 
are not going to get anything in return for doing such a, tak-
ing so much time to fill out the questionnaires and providing 
blood and doing the physical assessment. A lot of the par-
ticipants,... they would be very interested in getting return of 
results. So, we, apart from the return of results that they get 
from the clinical assessment centres at the time of the assess-
ment, we don’t return anything to the participants. So we 
don’t provide, you know, a risk based on genetic analysis or 
anything of that sort. So that I think, that would have been, 
if it would be possible, would be interesting for participants. 
A lot of them have asked us to provide such information. (In-
terviewee, 2014)
For example in a survey of Albertans (Caulfield et al. 
2012) most respondents were in the opinion that the re-
searcher should contact the person or a doctor if something 
about the individual’s health is discovered. Also the Tomor-
row Project has had a strategy not to return individual re-
search results. But due to a new research project that uses 
MRI scanning the TP has opted to re-consent participants 
and there are five abnormalities that in case found will be 
communicated to the participant and family doctor.
The engagement with the public happens also through 
channels that are not publicly visible or constitute from 
mundane practices. Talking with participants during sam-
ple taking, calling them for survey information and other 
personal contacts are highly important channels of com-
munication for biobanks.
A lot of the information I have is from the participants di-
rectly, so people who are interested in taking part in the study 
and people who have already participated in the study. So 
what we’ve done with the participants is send out a ques-
tionnaire asking them what their impression of the project 
was in general… I do rely on feedback from participants be-
cause, it gives you a direction, if something is really wrong, 
you’ll know about it. (Interviewee, 2014)
We do follow up on questionnaires, we follow up on missing 
information or unclear answers. It is to quality control. We do 
a lot of phoning, quality checks on data. If we hear a concern, 
we have regular meeting about them. (Interviewee, 2014)
An important aspect related to the sustainability of 
biobanks and engagement of people is related to the trans-
formations of institutions responsible of the biobanks and 
how biobanks become networked and incorporated into 
larger entities of biobanks. In the second phase of recruit-
ment of the Tomorrow Project, people who had participat-
ed in the first wave were asked a re-consent as the second 
wave recruitment coincided with the Tomorrow Project be-
coming part of the large Canadian consortium of CPTP - Ca-
nadian Partnership for Tomorrow Project. A significant part 
of the people declined to participate in the second wave. 
A common reason stated was that they had participated in 
an Albertan project. A similar local nationalistic attitude can 
be found in Quebec: 
I mean, I think that, the way the project was sort of market-
ed to the population in the beginning was saying that, we 
will construct the genetic map of Quebec. So, people who 
are part of this heritage are very proud to be part of this very 
Quebec, this very much Quebec project. And I think that, 
this is a big incentive for participants...that we need to be 
careful because obviously for how people understand the 
project, they have to know that we are CARTaGENE and it is 
a Quebec project but we are part of a larger initiative. And 
the data that they are providing and the specimens that 
they are providing may be used not only for researchers in 
Quebec that are using CARTaGENE but also for research-
ers across Canada and even internationally. (Interviewee, 
2014) 
The tendency in Canada is to form larger networks 
and entities of biobanks. Cooperation requires common 
strategies for data sharing, standardisation of sample tak-
ing, storage and analysis as well as merging of ethical prin-
ciples. One of the projects aiming at this is the P3G-IPAC 
project that has devised together with other international 
partners a “Framework for Responsible Sharing of Genomic 
and Health-Related Data” (2014). This framework is used in 
CPTP to enhance data sharing between the different Cana-
dian biobanks.
Besides taking stance on the public engagement, 
the framework serves the need of other stakeholders of 
biobanking. Clear frameworks and policies of access, data 
sharing and dissemination are highly relevant for the re-
searchers, institutions and companies using biobank data. 
Some of the biobanks are already sharing the data but 
biobanks such as the Tomorrow Project in Alberta is more 
or less still compiling data and has not in any ways mar-
keted the biobank to companies for example. Some of the 
most important stakeholders have been local research ethi-
cal boards and represnatatives from local governments and 
funding institutions.
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The focus of this research has been on engagement prac-
tices associated with biobanking around the world. More 
specifically, we have sought to understand some of the fac-
tors which may contribute to the long-term sustainability of 
these operations. A number of recent commentators have 
noted, that the life cycle of biobanks is tenuous and subject 
to external and internal pressures which may, ultimately, 
lead to the collapse of such operations (Tupasela and Ste-
phens 2013; Stephens 2011). Although biobank failure is 
rare, these findings indicate that biobanks go through a 
type of life cycle in which the cessation of activities is a 
distinct possibility if the multiple needs of biobanking are 
not adequately met. In addition, biobanks may transform 
over time and become associated to other institutions, be-
come networked or merged to other biobank entities or 
re-align their function and focus. Related to this, biobank-
ing activities may come under close and intense public 
scrutiny whereby their activities, legitimacy and operating 
procedures may come under public criticisms. In relation 
to long term sustainability, such crises of legitimacy and 
criticisms may have a significant impact on the operation 
of a biobank in particular, but also broader societal conse-
quences regarding levels of trust and legitimacy that may 
be associated with biomedical research in general.
Given these circumstances, we have sought to exam-
ine the engagement practices of different biobanks in six 
countries to identify important aspects related to the op-
eration of biobanks and the governance structures in which 
they operate. A short analysis of these practices has been 
presented above. As a qualitative study we have identified 
Discussion
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important themes which have presented themselves within 
the empirical material we have collected. These themes do 
not necessarily present themselves in all the cases, but we 
believe that they contribute in a substantive manner to the 
ways in which biobanking activities can be approached 
from a policy and governance level. Since the countries 
we have examined have very different histories, capaci-
ties, as well as governance and regulatory frameworks, and 
the biobanks examined represent population and clinical 
biobanks of various kinds, we do not take as our starting 
point, that the approach and subsequent analysis speaks 
to some definitive answer as to how biobanks ought to be 
governed or the ways in which they should manage their 
engagement strategies. But rather we see these as impor-
tant beacons or threads that can help illustrate the way 
biobank managers and personnel conceptualise their op-
erations and activities in the long run, as well as facilitate 
broader understanding among policy makers and funding 
organisations as to some of the challenges that relate to the 
long term sustainability of biobanking not just in Finland, 
but elsewhere as well.
Given this broader contextualisation we would like to 
suggest three important themes through which we feel the 
discussions regarding long term sustainability of biobank-
ing could be approached: broadening the concept of engage-
ment, engagement as dynamic and types of engagement.
Broadening the concept of engagement
Some scholars have noted that engagement is not a singu-
lar concept, but rather there are levels and styles in relation 
to the type of engagement that can be practiced (Thiel et al. 
2014). In our empirical material, we found, however, that en-
gagement is not only related to levels and styles, but should 
be conceptualised in a broader sense in relation to the ob-
ject of engagement as well. By this we mean to broaden 
the somewhat traditional notion of engagement, whereby 
the target or object of engagement is with patients or the 
public in general. This conceptualization of engagement 
has had it roots in particular forms of political aspirations 
and policy programmes which have sought to close the gap 
between science and society. Although we do not question 
the legitimacy and usefulness of such efforts, the findings 
in our study indicate that biobanks tend to engage much 
more with actors other than patients and the public. Ac-
cording to Cañada et al (forthcoming) biobanks engage 
with a broad spectrum of actors many of whom do not fall 
into the traditional category of the public. Instead some 
of the most notable engagement targets include funding 
agencies, regulatory actors, as well as the research and clini-
cal community from which samples are sourced. Many of 
these engagement targets have a profound impact on the 
wasy in which biobanks organize their activities, as well as 
the ethical, lecal and social context in which biobanking 
takes place. In this sens, it might be argued that the over-
emphasis in focus on public engagement has perhaps over-
shadowed the role that other actors play in the ways that 
biobanks operate and organize their day-to-day activities.
From a policy perspective this has important implica-
tions in terms of identifying the social role and significance 
of biobanks in general. Given the broad societal networks 
that biobanks need to maintain in order to make sure that 
their activities continue in the long-term, biobanks need 
to engage with a broad range of stakeholders. The pub-
lic, research participants and patients are only part of this 
stakeholder group. In the day-to-day activities of biobanks, 
broader engagement with the public becomes often of 
secondary importance as the engagement with funders, 
research ethics boards, companies and other biobanks 
takes up all the time and resources. From a public policy 
perspective, however, the public still maintains a special 
profile as a target of engagement since much of the public 
trust and legitimacy in relation to long-term sustainability 
is drawn from that group. In relation to short-term goals, 
however, other engagement groups represent and require 
significant resources and efforts from biobanks to maintain 
various forms of engagement.
Engagement as dynamic
In addition to broadening the concept of engagement to 
include a larger set of actors with whom biobanks engage 
with, the study also identified important elements which 
relate to the dynamics of engagement in relation to time 
and temporality. A number of the biobanks and tissue 
collections that we have examined in our study indicate 
that current biobanking activities often build upon exist-
ing activities which were derived from previous projects, 
collections, samples or information. This is the case of Ice-
land’s deCode, which was founded and based on earlier 
research, as well as smaller sample collections (see section 
on Iceland) or the Auria biobank in Turku, which is based 
on moving diagnostic samples that the Pirkanmaan hospi-
tal disctrict has collected for decades into an institutional 
entity (called a biobank) and which is governed by the new 
law on biobanking in Finland (see section on Finland). Fol-
lowing this line, Spanish biobanks saw their dynamics and 
activity changed at a very specific point in time marked by 
the creation of the Biomedical Research Law. All previous 
activities and collected samples had to therefore adapt to 
fit the requirements stated by the law. These changes over 
time point to a salient feature regarding biobanks, namely 
that they tend to have a type of life cycle which is dynamic 
in relation to time and temporality. By dynamic we simply 
mean that biobanking is not necessarily a set of stable prac-
tices in which tissue samples and information are collected 
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and circulate, but rather they are in a more or less constant 
state of flux whereby their practices and governance struc-
tures are continually ‘evolving’ to meet new needs by the 
research community, funding organisations, regulators, as 
well as participants and the public. In this dynamic model 
of biobanking, the public and patients represent only one, 
albeit important, aspect of biobanking.
The notion that biobanking and its activities are dy-
namic has a number of important consequences when we 
consider it in relation to the broadened notion of engage-
ment. First, as biobanks go through transformative pro-
cesses, so do the requirements and expectations that are 
associated with their activities. The operational and practi-
cal requirements that are necessary for managing small re-
search collections can be vastly different than those that are 
associated with larger collections. As collection go through 
transformative processes they may encounter tensions and 
frictions as to the definitions of their purpose and function, 
as well as contention over control and management of the 
samples and information themselves (cf. Hoeyer 2004). Fur-
thermore, the changes that collections undergo may have 
significant consequnces in relation to institutional identity 
and roles as it relates to the practices that take place with 
biobanking. This can be seen particularly in the clinical set-
ting in hospitals where biobanking activities become em-
bedded in everyday clinical care. The intergration of such 
activities has been show to have significant impact on the 
expectations associated with the delivery of healthcare re-
sults deriving from genetic research and clinical practice 
(Pullman and Hodgkins 2006).
Second, the dynamics associated with biobanks also 
relate to the ways in which biobanks positions themselves 
within the broader markets for tissue collections and their 
availability. Biobanking is increasingly premised on net-
works of biobanks, such as BBMRI, which suggests that the 
dynamics of engagement are also elaborated within broad-
er social and technical networks through which standards 
and best practices emerge and become codified in various 
ways (Mayerhofer and Prainsack 2009). The dynamics of 
moving from a singular entity into a broader global market 
of biobanks also entails a necessary broadening of actors 
with whom to engage with. It is also important to note 
that there are numerous different biobank networks that 
biobanks may belong to the dynamics related to the com-
petition and cooperation among those networks can also 
have a significant impact on the ways in which biobanks 
develop their activities.
Third, as repositories which seek to preserve and main-
tain samples and information for later use, the temporality 
of biobanks and their need to stabilize or freeze samples in 
time poses a subsequent challenge in relation to dynamics. 
Given the transformative changes that collections some-
times need to go through, a considerable amount of work 
goes into negotiating the space and time between the fixed/
preserved/frozen samples and the dynamic of the engage-
ment processes involved in transformations. Within this ten-
uous process, samples and information exit and enter new 
‘zones’ of governance where a broader set of engaged actors 
and practices are needed in order to assure sustainability 
(from small to large; public to private or a hybrid etc…). Sam-
ples collected today and which may be developed into cell 
lines in 10 or 20 years may meet the ethical and legal gov-
ernance frameowkrs of today, but the landscape that they 
enter into when activated or revitalized may be significantly 
different than that of today. In this sense biobanks are con-
tinually positioning themselves in a way that is rooted in the 
past, but which must also consider the future.
Fourth, dynamics is linked very much to the expecta-
tions, attitudes and opinions of the public towards biobank-
ing. Research among publics in different countries has 
shown that people are interested, worried and enthusiastic 
about future prospects of biobanking (Snell et al. 2012). In-
stead of worrying about how their personal information is 
being handled currently, many people expressed concerns 
about the future governance of biobanks: Who gets to use 
the samples and information in the future? What happens 
to the samples if a publicly funded biobank becomes pri-
vatized? What kind of a world are we creating with biobank 
research? Thus many of the public’s concerns are related to 
the sustainability of biobanks.
Types of Public Engagement 
In conceptualising engagement practices in different coun-
tries and between various biobanks we have developed a 
typology of public engagement in which we have sought 
to classify various types of public engagement (Snell et al. 
2012). Our research shows that in addition to large public 
communication events and involving the public in decision-
making, engagement takes place in mundane practices and 
private situations, such as face-to-face contacts with donors 
and sample takers, as well as patients’ visits to the clinic. En-
gagement happens also outside the official protocols and 
strategies in either unexpected or routine situations that 
may be out of control of the biobanks.
Our starting point for analysis has been the typology 
of public engagement developed by Rowe and Frewer 
(2005) that distinguishes between public communication, 
public consultation and public participation. In their typol-
ogy, they focus on the flow and nature of information that 
is mediated and the effectiveness of different types of pub-
lic engagement. Consequently they identify variables that 
help to maximise information transfer or the number of 
participants in public engagement. According to them, in 
public communication, information is conveyed from the 
initiators of the communication to the public. Thus the In-
formation flow is a one-way process and public feedback 
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is not required or even sought unlike with public consulta-
tion, where information is conveyed from members of the 
public. As regards to public participation, information is ex-
changed between members of the public and the initiators 
of the discussions so that there is some degree of dialogue. 
Participation aims at dialogue and negotiation that serves 
to transform opinions in the members of both parties. 
Within this framework we have added three dimen-
sions which further elaborate on the nature of biobank en-
gagement. These dimensions are open vs private/restricted 
engagement, official vs unofficial forms of engagement and 
finally direct vs mediated forms of engagement. Below we 
have constructed a table (Table 4) where we describe the 
wasy in which our three categories complement Rowe and 
Frewers (2005) original conceptualisatin of engagement 
practices.
With open vs private engagement we seek to distin-
guish between the type of engagement one tends to be 
able to observe and recount through publically accessible 
information, such as webpages, versus the often quite and 
behind the scenes type of engagement which is more per-
sonal and often is mediated through tacit forms of knowl-
edge transfer between, for example, clinicians and patients. 
Our categorisations of official vs unofficial forms of 
engagement relate to the ways in which engagement is 
structured through various governance and social interac-
tion frameworks. Official forms of engagement include the 
processes of gaining informed consent, information dis-
semination to participants, as well as the protocols which 
may have been put in place to ensure that biobanks meet 
some level of minimum requirement in terms of engaging 
with the research population. Unofficial forms of govern-
ance, however, can be seen as forms of engagemernt which 
biobanks may undertake to increase trust and legitimacy, 
but which may not be required by ethical and legal norms 
and standards. These forms of engagement may include a 
broad range of activities ranging from sending out newslet-
ters to organizing patient evenings and open house events 
for the public.
Finally, the notions of direct vs mediated forms of en-
gagement relate to the distance between the biobank itself 
and its source of sample and information. Often informa-
tion is mediated through various types of media. Some 
biobanks engage directly with their research population, 
collecting samples and information themselves, while oth-
ers operate through clinicians or hospitals which mediate 
the process as well as the information that patients or do-
nors receive regarding the biobanks and what is done with 
samples. As we noted above, for some biobanks, maintain-
ing some distance to the research population is an explicit 
strategy through which the organization seeks to maintain 
independence and organizational clarity, whereas with 
other biobanks, such as deCode, the process of collecting 
samples and information may form an important part of 
their organizational identity and responsibility towards the 
research population.
Table 4. Engagement matrix.
Public Communication Public consultation Public participation
Official
Forms of engagement that 
are regulated, standardised 
or use a specific protocol
1. Informed consent,  
registry information &  
official documents
2. Informed consent,
Sample and health data 
collection
3. Lay representation  
in biobank boards
Unofficial
Unregulated or sporadic 
encounters 
4. Media coverage,
mobile games, newsletters 
5. Social media, personal 
enquiries
6. Open seminars and 
discussions
Open
Forms that are open or 
available to all, or information 
about engagement is 
available openly
7. Web pages, newsletters, 
posters, registry information 
& official documents,  
media coverage
8. Open feedback through 
i.e. web pages, social media
9. Open public seminars  
and discussions
Private/restricted 
Personal encounters, 
or engagement that is 
not publicly available or 
manifested
10. Re-contact, return of 
research results, platforms
11. Surveys and focus groups
Personal enquiries, doctors’ 
appointments
12. Personal encounters  
with biobank, medical or 
research staff
Lay representation in boards
Direct
Biobanks engage directly 
with the public
13. Informed consent,  
re-contact, newsletters, 
14. Feedback to biobanks, 
social media, phone calls  
to participants 
15. Public stakeholder 
seminars of biobanks
Mediated
Facilitated through another 
actor, mediator, intermediary
16. Legislation, media 
coverage, doctors & nurses
‘Biobank ambassadors’
17. Visits to the recruitment 
centers
Social research and opinion 
surveys
18. Biobank evenings in  
the media
Lay representation in 
biobank boards
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This study has sought to study and explore engage-
ment practices undertaken by biobanks in six different 
countries. The biobanks we have examined represent a 
very broad spectrum of actors with very different types 
of inditutional setting, as well as histories relating to their 
conceptions. Our findings indicate that engagement is not 
a singular concept or activity; there are levels and styles in 
relation to the type of engagement that can be practiced. 
Our empirical material has shown that engagement is not 
only related to levels and styles, but should be conceptual-
ized in a broader sense in relation to the object of engage-
ment as well. By this we mean to broaden the notion of 
engagement, where the target or object of engagement 
is with patients or the public in general. This conceptual-
ization of engagement has had it roots in particular forms 
of political aspirations and policy programs which have 
sought to close the gap between science and society. We 
recognize public engagement as being a highly relevant 
aspect of biobank engagmenet, but highlighting the oth-
er types of engagement provides understanding of how 
public engagement fits into the practices of biobanking 
and what are the priorities of different biobanks. In order 
to secure the long-term sustainability of biobanking a 
broader understanding of conditions for engagement is 
needed - wether it is public engagement or engagement 
with other stakeholders.
Our study has also identified important elements 
which relate to the dynamics of engagement as they relate 
to time and temporality. Over time, biobanks go through 
transformative processes where collections may encounter 
tensions and frictions as to the definitions of their purpose 
and function. The dynamics associated with biobank net-
works impact engagement practices, whereby moving from 
a singular entity into a broader global market of biobanks, 
for example, entails a necessary broadening of actors with 
whom to engage with. When repositories preserve and 
maintain samples and information for later use, a consid-
erable amount of work goes into negotiating the space 
and time between the fixed/preserved/frozen samples 
and the dynamic of the engagement processes involved 
in transformations. Within this tenuous process, samples 
and information exit and enter new ‘zones’ of governance 
where a broader set of engaged actors (regulators, ethics 
committees) and practices are needed in order to assure 
long-term sustainability. We see these findings as provid-
ing important insight into the development of long-term 
sustainable practices in Finnish biobanking.
Although our study did not find clear evidence as to 
the relationship between engagement strategy and long-
term sustainability, there appears none-the-less to be a 
trend within the field of biobanking towards policies which 
encourage the development of engagement strategies. 
Furthermore, it is important to note that within the com-
mercial biobanking sector, there is a strong push to develop 
activities which draw on social media and other technolo-
gies to provide increased levels of feedback to participants. 
This general trend may place increased pressure on public 
research organisations to provide and develop competing 
forms of engagement strategies and practices in order to 
compete with private industry, as well as retain and main-
tain a trusting and happy research population. Although it 
is unlikely that private industry will be able to gain access 
or create biobanking collections which are as extensive as 
those produced by the public sector (hospitals and research 
insitutions for example), they are able to provide proof of 
concept like practices which may have an impact on the 
expectations that the general public, as well as patients in 
general may have in relation to participation and contribu-
tion to biobanking activities in the future. It would there-
fore be prudent for biobanks operating in the public sector 
to develop strategies which seek to develop engagement 
practices with their research populations. These strategies 
may be very different depending on the type of biobank-
ing activity that is involved. The key, however, is to work 
towards opening and maintaining different lines of com-
munication to and from the public.
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